Movatterモバイル変換


[0]ホーム

URL:


LTC2456444I2 - - Google Patents

Info

Publication number
LTC2456444I2
LTC2456444I2LTPA2021526CLTPA2021526CLTC2456444I2LT C2456444 I2LTC2456444 I2LT C2456444I2LT PA2021526 CLTPA2021526 CLT PA2021526CLT PA2021526 CLTPA2021526 CLT PA2021526CLT C2456444 I2LTC2456444 I2LT C2456444I2
Authority
LT
Lithuania
Application number
LTPA2021526C
Original Assignee
Intellikine, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellikine, LlcfiledCriticalIntellikine, Llc
Publication of LTPA2021526I1publicationCriticalpatent/LTPA2021526I1/lt
Publication of LTC2456444I2publicationCriticalpatent/LTC2456444I2/lt

Links

Classifications

Landscapes

LTPA2021526C2009-07-152021-11-11LTC2456444I2 (lt)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US12/503,776US8193182B2 (en)2008-01-042009-07-15Substituted isoquinolin-1(2H)-ones, and methods of use thereof
PCT/US2010/002020WO2011008302A1 (en)2009-07-152010-07-15Certain chemical entities, compositions and methods

Publications (2)

Publication NumberPublication Date
LTPA2021526I1 LTPA2021526I1 (lt)2021-12-10
LTC2456444I2true LTC2456444I2 (lt)2024-11-25

Family

ID=43450336

Family Applications (1)

Application NumberTitlePriority DateFiling Date
LTPA2021526CLTC2456444I2 (lt)2009-07-152021-11-11

Country Status (33)

CountryLink
US (13)US8193182B2 (lt)
EP (4)EP3441392B1 (lt)
JP (2)JP5944313B2 (lt)
KR (1)KR101680406B1 (lt)
CN (3)CN106188059B (lt)
AU (1)AU2010274075B2 (lt)
BR (1)BR112012000968B8 (lt)
CA (1)CA2768307C (lt)
CY (2)CY1116424T1 (lt)
DK (1)DK2456444T3 (lt)
ES (1)ES2538853T3 (lt)
FI (1)FIC20210039I1 (lt)
HR (1)HRP20150586T1 (lt)
HU (1)HUS2100048I1 (lt)
IL (2)IL217181A (lt)
IN (1)IN2012DN00943A (lt)
LT (1)LTC2456444I2 (lt)
LU (1)LUC00237I2 (lt)
MX (3)MX2012000626A (lt)
MY (2)MY168762A (lt)
NL (1)NL301140I2 (lt)
NO (1)NO2021047I1 (lt)
NZ (3)NZ597595A (lt)
PH (2)PH12015502432A1 (lt)
PL (1)PL2456444T3 (lt)
PT (1)PT2456444E (lt)
RU (2)RU2746319C2 (lt)
SG (2)SG10201503886WA (lt)
SI (1)SI2456444T1 (lt)
SM (1)SMT201500141B (lt)
UA (2)UA109878C2 (lt)
WO (1)WO2011008302A1 (lt)
ZA (1)ZA201200254B (lt)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
MXPA05007322A (es)*2003-01-062006-02-17Angiochem IncAprotinina y analogos como portadores a traves de la barrera sangre-cerebro.
US9512125B2 (en)2004-11-192016-12-06The Regents Of The University Of CaliforniaSubstituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US7834181B2 (en)*2005-02-012010-11-16Slaon-Kettering Institute For Cancer ResearchSmall-molecule Hsp90 inhibitors
US9403828B2 (en)2005-02-012016-08-02Sloan-Kettering Institute For Cancer ResearchSmall-molecule Hsp90 inhibitors
GB0509573D0 (en)*2005-05-112005-06-15Merck Sharp & DohmeTherapeutic compounds
CA2614687C (en)2005-07-152016-03-22Angiochem Inc.Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
ES2423010T3 (es)2006-04-042013-09-17The Regents Of The University Of CaliforniaDerivados de pirazolopirimidina para su uso como antagonistas de cinasa
US9365634B2 (en)*2007-05-292016-06-14Angiochem Inc.Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
GB2467670B (en)2007-10-042012-08-01Intellikine IncChemical entities and therapeutic uses thereof
US8193182B2 (en)2008-01-042012-06-05Intellikine, Inc.Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101660050B1 (ko)2008-01-042016-09-26인텔리카인, 엘엘씨특정 화학 물질, 조성물 및 방법
US8993580B2 (en)*2008-03-142015-03-31Intellikine LlcBenzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja)2008-03-142014-07-09インテリカイン, エルエルシーキナーゼ阻害剤および使用方法
CN102026667B (zh)2008-04-182014-06-25安吉奥开米公司紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
NZ590258A (en)2008-07-082013-10-25Intellikine LlcKinase inhibitors and methods of use
US20110224223A1 (en)2008-07-082011-09-15The Regents Of The University Of California, A California CorporationMTOR Modulators and Uses Thereof
CA2738429C (en)2008-09-262016-10-25Intellikine, Inc.Heterocyclic kinase inhibitors
WO2010043049A1 (en)2008-10-152010-04-22Angiochem Inc.Etoposide and doxorubicin conjugates for drug delivery
EP2346906A4 (en)2008-10-152013-04-24Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
EP2358720B1 (en)2008-10-162016-03-02The Regents of The University of CaliforniaFused ring heteroaryl kinase inhibitors
SI2350071T1 (sl)2008-10-222014-05-30Array Biopharma, Inc.Substituirane pirazolo(1,5-a)pirimidinske spojine kot Trk kinazni inhibitorji
US8476431B2 (en)2008-11-032013-07-02Itellikine LLCBenzoxazole kinase inhibitors and methods of use
MX2011005963A (es)2008-12-052011-09-01Angiochem IncConjugados de neurotensina o analogos de neurotensina y sus usos.
JP2012512185A (ja)2008-12-172012-05-31アンジオケム インコーポレーテッド膜1型マトリックス金属タンパク質阻害剤およびその使用
US20110135655A1 (en)*2009-01-132011-06-09PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine;Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
CA2751892A1 (en)2009-01-152010-07-22Rutgers, The State University Of New JerseyBenzo [c] phenanthridines as antimicrobial agents
BRPI1015295A2 (pt)2009-04-202016-05-31Angiochem Inctraamento de câncer de ovário usando um agente anticâncer conjugado a um análogo angiopep-2.
WO2010127307A1 (en)2009-04-302010-11-04Rutgers, The State University Of New JerseyAntimicrobial agents
CA2760791C (en)2009-05-072017-06-20Intellikine, Inc.Heterocyclic compounds and uses thereof
CN104945420A (zh)2009-06-292015-09-30因塞特公司作为pi3k抑制剂的嘧啶酮类
BRPI1015918A2 (pt)2009-07-022019-09-24Angiochem Incconjugados de peptídeo multiméricos e usos dos mesmos
JP2011232320A (ja)*2009-10-012011-11-17Sony Corp生体内物質検出用プローブ、および該生体内物質検出用プローブを用いた生体内物質検出装置
WO2011047384A2 (en)2009-10-162011-04-21The Regents Of The University Of CaliforniaMethods of inhibiting ire1
WO2011075643A1 (en)2009-12-182011-06-23Incyte CorporationSubstituted heteroaryl fused derivatives as pi3k inhibitors
EP2544672A1 (en)2010-03-092013-01-16OSI Pharmaceuticals, LLCCombination anti-cancer therapy
CA2796311A1 (en)2010-04-142011-10-20Incyte CorporationFused derivatives as pi3k.delta. inhibitors
ES2593256T3 (es)*2010-05-212016-12-07Infinity Pharmaceuticals, Inc.Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CA2810162A1 (en)2010-06-092011-12-15Rutgers, The State University Of New JerseyAntimicrobial agents
WO2011159926A1 (en)*2010-06-162011-12-22Rutgers, The State University Of New JerseyAntimicrobial agents
WO2011163195A1 (en)2010-06-212011-12-29Incyte CorporationFused pyrrole derivatives as pi3k inhibitors
WO2011163610A2 (en)2010-06-252011-12-29Rutgers, The State University Of New JerseyAntimicrobial agents
AU2011326427B2 (en)2010-11-102016-01-07Infinity Pharmaceuticals Inc.Heterocyclic compounds and uses thereof
WO2012087881A1 (en)2010-12-202012-06-28Incyte CorporationN-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
NZ612909A (en)*2011-01-102015-09-25Infinity Pharmaceuticals IncProcesses for preparing isoquinolinones and solid forms of isoquinolinones
AU2015258280B2 (en)*2011-01-102017-07-20Infinity Pharmaceuticals Inc.Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN103491962B (zh)2011-02-232016-10-12因特利凯有限责任公司激酶抑制剂的组合及其用途
US20140213630A1 (en)2011-03-082014-07-31Thomas DiacovoMethods and pharmaceutical compositions for treating lymphoid malignancy
WO2012125629A1 (en)2011-03-142012-09-20Incyte CorporationSubstituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US8653299B2 (en)*2011-03-172014-02-18Allergan, Inc.Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
WO2012135009A1 (en)2011-03-252012-10-04Incyte CorporationPyrimidine-4,6-diamine derivatives as pi3k inhibitors
MX345238B (es)2011-03-282017-01-23Mei Pharma Inc(aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
EP2734520B1 (en)2011-07-192016-09-14Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
CA2842190A1 (en)*2011-07-192013-01-24Infinity Pharmaceuticals Inc.Heterocyclic compounds and uses thereof
MX2014002542A (es)*2011-08-292014-07-09Infinity Pharmaceuticals IncCompuestos heterociclicos y usos de los mismos.
CA2846272A1 (en)*2011-09-012013-03-07Novartis AgPi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone
CA2846496C (en)2011-09-022020-07-14The Regents Of The University Of CaliforniaSubstituted pyrazolo[3,4-d]pyrimidines and uses thereof
TWI717002B (zh)2011-09-022021-01-21美商英塞特控股公司作為pi3k抑制劑之雜環基胺
US20130072506A1 (en)*2011-09-162013-03-21Lenka ZAHAJSKA6,8-disubstituted purine compositions
US9630979B2 (en)2011-09-292017-04-25Infinity Pharmaceuticals, Inc.Inhibitors of monoacylglycerol lipase and methods of their use
HK1201271A1 (en)*2011-11-112015-08-28Intellikine, LlcKinase inhibitor polymorphs
US9039898B2 (en)*2011-11-152015-05-26Engineering Research Associates, Inc.Method for separating components in natural oil
CA2857302C (en)2011-12-152020-08-25Novartis AgUse of inhibitors of the activity or function of pi3k
WO2013106756A2 (en)2012-01-132013-07-18Rutgers, The State University Of New JerseyAntimicrobial agents
EP2828245A1 (en)2012-03-212015-01-28Rutgers, The State University of New JerseyAntimicrobial agents
AR090548A1 (es)2012-04-022014-11-19Incyte CorpAzaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2013152342A1 (en)2012-04-062013-10-10OSI Pharmaceuticals, LLCAnti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en)*2012-04-102015-01-27Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
CA2868392A1 (en)2012-05-232013-11-28Estelle DOUDEMENTCompositions and methods of obtaining and using endoderm and hepatocyte cells
US8828998B2 (en)*2012-06-252014-09-09Infinity Pharmaceuticals, Inc.Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR20150034209A (ko)2012-06-262015-04-02델 마 파마슈티컬스 인코포레이티드디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
RU2015115631A (ru)2012-09-262016-11-20Дзе Риджентс Оф Дзе Юниверсити Оф КалифорнияМодулирование ire1
US20140120083A1 (en)*2012-11-012014-05-01Infinity Pharmaceuticals, Inc.Treatment of cancers using pi3 kinase isoform modulators
US20150283142A1 (en)*2013-03-152015-10-08Infinity Pharmaceuticals, Inc.Treatment of cancers using pi3 kinase isoform modulators
US20140120060A1 (en)2012-11-012014-05-01Infinity Pharmaceuticals, Inc.Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
PL2914296T5 (pl)2012-11-012022-01-17Infinity Pharmaceuticals, Inc.Leczenie nowotworu z zastosowaniem modulatorów izoform kinazy PI3
EP2916868B1 (en)2012-11-082022-05-11Rhizen Pharmaceuticals S.A.Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
EP2935246B1 (en)2012-12-212018-07-25Gilead Calistoga LLCIsoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
US9018221B2 (en)2012-12-212015-04-28Gilead Calistoga, LlcPhosphatidylinositol 3-kinase inhibitors
DK2948134T3 (da)2013-01-242020-06-02Palvella Therapeutics IncSammensætninger til transdermal indgivelse af mtor-inhibitorer
WO2014151386A1 (en)2013-03-152014-09-25Infinity Pharmaceuticals, Inc.Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9481667B2 (en)*2013-03-152016-11-01Infinity Pharmaceuticals, Inc.Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014168986A1 (en)2013-04-082014-10-16Brown Dennis MTherapeutic benefit of suboptimally administered chemical compounds
US20140377258A1 (en)*2013-05-302014-12-25Infinity Pharmaceuticals, Inc.Treatment Of Cancers Using PI3 Kinase Isoform Modulators
EA028319B1 (ru)2013-06-142017-11-30Джилид Калистога ЛлсИнгибиторы фосфатидилинозитол-3-киназы
CN105431437B (zh)2013-07-022020-03-10理森制药股份公司PI3K蛋白激酶抑制剂,特别是δ抑制剂和/或γ抑制剂
SG11201600028YA (en)*2013-09-222016-02-26Calitor Sciences LlcSubstituted aminopyrimidine compounds and methods of use
PH12016500582B1 (en)2013-10-042023-06-30Infinity Pharmaceuticals IncHeterocyclic compounds and uses thereof
WO2015051241A1 (en)*2013-10-042015-04-09Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
US20160244452A1 (en)2013-10-212016-08-25Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
US9458150B2 (en)2013-11-082016-10-04Rutgers, The State University Of New JerseyAntimicrobial agents
CA2931615A1 (en)2013-11-262015-06-04Gilead Sciences, Inc.Therapies for treating myeloproliferative disorders
BR112016012794A2 (pt)2013-12-052017-08-08Acerta Pharma BvCombinação terapêutica de um inibidor de pi3k e um inibidor de btk
EP3096757B1 (en)2014-01-242020-10-21AI Therapeutics, Inc.Apilimod compositions for treating non-hodgkin's b cell lymphoma
CN104817559B (zh)*2014-01-302021-05-25苏州泽璟生物制药股份有限公司氘代喹唑啉酮化合物以及包含该化合物的药物组合物
CN113616656B (zh)2014-03-192023-02-17无限药品股份有限公司用于治疗PI3K-γ介导的障碍的杂环化合物
WO2015181633A2 (en)2014-04-112015-12-03Acerta Pharma B.V.Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en)2014-04-112015-12-10Acerta Pharma B.V.Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
WO2015160975A2 (en)2014-04-162015-10-22Infinity Pharmaceuticals, Inc.Combination therapies
WO2015160986A2 (en)2014-04-162015-10-22Infinity Pharmaceuticals, Inc.Combination therapies
WO2015168079A1 (en)2014-04-292015-11-05Infinity Pharmaceuticals, Inc.Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2015179772A1 (en)2014-05-232015-11-26Concert Pharmaceuticals, Inc.Deuterated phenylquinazolinone and phenylisoquinolinone compounds
WO2015191677A1 (en)2014-06-112015-12-17Incyte CorporationBicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
NZ726360A (en)2014-06-132018-04-27Gilead Sciences IncPhosphatidylinositol 3-kinase inhibitors
EP3154969B1 (en)2014-06-132019-10-09Gilead Sciences, Inc.Phosphatidylinositol 3-kinase inhibitors
WO2015191752A1 (en)2014-06-132015-12-17Gilead Sciences, Inc.Phosphatidylinositol 3-kinase inhibitors
KR20170015508A (ko)2014-06-132017-02-08길리애드 사이언시즈, 인코포레이티드포스파티딜이노시톨 3-키나제 억제제로서의 퀴나졸리논 유도체
WO2015193740A2 (en)*2014-06-172015-12-23Acerta Pharma B.V.Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
AU2015277786B2 (en)2014-06-192019-04-18Takeda Pharmaceutical Company LimitedHeteroaryl compounds for kinase inhibition
MX2016017110A (es)*2014-06-242017-05-01Gilead Sciences IncInhibidores de fosfatidilinositol 3-cinasa.
HK1232227A1 (zh)2014-07-042018-01-05Lupin Limited作为pi3k抑制剂的喹嗪酮衍生物
WO2016020901A1 (en)2014-08-072016-02-11Acerta Pharma B.V.Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
WO2016024232A1 (en)2014-08-112016-02-18Acerta Pharma B.V.Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
WO2016024227A1 (en)2014-08-112016-02-18Acerta Pharma B.V.Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
SI3179991T1 (sl)2014-08-112022-04-29Acerta Pharma B.V.Terapevtske kombinacije zaviralca BTK in zaviralca BCL-2
DK3179992T3 (da)2014-08-112022-07-11Acerta Pharma BvTerapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
CN104211663B (zh)*2014-08-112017-01-11杭州偶联医药科技有限公司一种(s)-n-甲氧基-甲基-2-(四氢吡咯基)丙酰胺及其制备方法和应用
HUE049480T2 (hu)2014-09-032020-09-28Rhizen Pharmaceuticals S AKezelési eljárás és kettõs specifitású PI3K Delta-Gamma kináz inhibitort és kortikoszteroidot tartalmazó készítmények
US9950194B2 (en)2014-09-092018-04-24Mevion Medical Systems, Inc.Patient positioning system
EP3193902A4 (en)2014-09-112018-03-28The Regents of The University of CaliforniamTORC1 INHIBITORS
CN105503877A (zh)2014-09-242016-04-20和记黄埔医药(上海)有限公司咪唑并哒嗪类化合物及其用途
WO2016054491A1 (en)2014-10-032016-04-07Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
WO2016055982A1 (en)2014-10-102016-04-14Acerta Pharma B.V.Quinoline and quinazoline compounds
EP3215158B1 (en)2014-11-072019-05-08AI Therapeutics, Inc.Apilimod for use in the treatment of renal cancer
WO2016087994A1 (en)2014-12-052016-06-09Acerta Pharma B.V.Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
HRP20210036T1 (hr)2015-02-272021-03-05Incyte CorporationSoli inhibitora pi3k i postupci za njihovo dobivanje
US9988401B2 (en)2015-05-112018-06-05Incyte CorporationCrystalline forms of a PI3K inhibitor
US9732097B2 (en)2015-05-112017-08-15Incyte CorporationProcess for the synthesis of a phosphoinositide 3-kinase inhibitor
JP6823055B2 (ja)2015-06-152021-01-27アンジオケム インコーポレーテッド軟髄膜癌腫症の治療方法
EP3334430B1 (en)*2015-08-132025-02-26San Diego State University Research FoundationAtropisomerism for increased kinase inhibitor selectivity
US20190008859A1 (en)2015-08-212019-01-10Acerta Pharma B.V.Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
JP6980649B2 (ja)2015-09-142021-12-15インフィニティー ファーマシューティカルズ, インコーポレイテッドイソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
MA44909A (fr)2015-09-152018-07-25Acerta Pharma BvAssociation thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
WO2017046746A1 (en)2015-09-152017-03-23Acerta Pharma B.V.Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
MA43162A (fr)2015-11-062018-09-12Acerta Pharma BvInhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
CN108699061B (zh)*2015-11-162022-07-05纽弗姆制药有限公司用于治疗血液恶性肿瘤、炎症和自身免疫性疾病的氘代化合物
KR101767260B1 (ko)*2015-12-222017-08-10한국화학연구원피리미도 옥사진 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
DK3402503T3 (da)2016-01-132020-12-21Acerta Pharma BvTerapeutiske kombinationer af et antifolat og en btk-hæmmer
WO2017147316A1 (en)2016-02-252017-08-31Taxis Pharmaceuticals, Inc.Synthetic processes and intermediates
WO2017161116A1 (en)2016-03-172017-09-21Infinity Pharmaceuticals, Inc.Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
MX386416B (es)2016-04-042025-03-18Loxo Oncology IncFormulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
US10045991B2 (en)2016-04-042018-08-14Loxo Oncology, Inc.Methods of treating pediatric cancers
HRP20221051T8 (hr)2016-04-152023-07-21Cancer Research Technology LimitedHeterociklički spojevi kao inhibitori ret kinaze
MX387394B (es)2016-04-152025-03-18Cancer Research Tech LtdCompuestos heterociclicos como inhibidores de la cinasa ret.
WO2017214269A1 (en)*2016-06-082017-12-14Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
IL263680B1 (en)2016-06-242025-06-01Infinity Pharmaceuticals IncPi3k inhibitors for use in combination with a second therapeutic agent in treating, managing, or preventing cancer
AU2017296016A1 (en)*2016-07-112019-01-24Hennepin Life Sciences, LlcCompositions for sexually transmitted diseases
TW201813963A (zh)2016-09-232018-04-16美商基利科學股份有限公司磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh)2016-09-232018-07-16美商基利科學股份有限公司磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh)2016-09-232018-05-01美商基利科學股份有限公司磷脂醯肌醇3-激酶抑制劑
JP7108631B2 (ja)2017-01-062022-07-28パルヴェラ セラピューティクス、インク.mTOR阻害剤の無水組成物およびその使用方法
US20220235013A1 (en)*2017-03-212022-07-28Bayer Pharma Aktiengesellschaft2-methyl-quinazolines
CA3058183A1 (en)2017-03-302018-10-04Taxis Pharmaceuticals, Inc.Synthetic processes and synthetic intermediates
RU2640579C1 (ru)*2017-04-102018-01-10Феркат Адельзянович ХалиуллинГИДРОХЛОРИДЫ 1-АЛКИЛ-3-МЕТИЛ-8-ПИПЕРАЗИНО-7-(ТИЕТАНИЛ-3)КСАНТИНА, ПРОЯВЛЯЮЩИЕ АНТИТРОМБОТИЧЕСКИЙ ЭФФЕКТ ПОСРЕДСТВОМ БЛОКИРОВАНИЯ РЕЦЕПТОРОВ ТРОМБОЦИТОВ ГП IIb-IIIa
GB201705971D0 (en)*2017-04-132017-05-31Cancer Res Tech LtdInhibitor compounds
MX2019013862A (es)2017-05-232020-01-20Mei Pharma IncTerapia de combinacion.
RU2020108454A (ru)*2017-07-312021-09-02Дзе Трастиз Оф Коламбия Юниверсити Ин Дзе Сити Оф Нью ЙоркСоединения, композиции и способы лечения t-клеточного острого лимфобластного лейкоза
KR20200041358A (ko)2017-08-142020-04-21메이 파마, 아이엔씨.병용 요법
WO2019143874A1 (en)2018-01-202019-07-25Sunshine Lake Pharma Co., Ltd.Substituted aminopyrimidine compounds and methods of use
EP3788050B1 (en)2018-05-012024-08-28Revolution Medicines, Inc.C26-linked rapamycin analogs as mtor inhibitors
EP4234031A3 (en)2018-05-012024-02-28Revolution Medicines, Inc.C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
WO2019232223A1 (en)2018-05-302019-12-05University Of Notre Dame Du LacHsp90 beta selective inhibitors
MA52761A (fr)2018-06-012021-04-14Incyte CorpSchéma posologique destiné au traitement de troubles liés à la pi3k
WO2019239374A1 (en)2018-06-132019-12-19Acerta Pharma B.V.Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
JP2021530463A (ja)2018-07-022021-11-11パルヴェラ セラピューティクス、インク.mTOR阻害剤の無水組成物および使用方法
CN110833549B (zh)*2018-08-152023-05-02广西梧州制药(集团)股份有限公司吡唑并嘧啶衍生物在治疗慢性盆腔炎的用途
AU2019407426A1 (en)2018-12-212021-07-22Daiichi Sankyo Company, LimitedCombination of antibody-drug conjugate and kinase inhibitor
CN112194659A (zh)2019-07-082021-01-08浙江海正药业股份有限公司炔类衍生物及其制备方法和用途
WO2021201574A1 (ko)*2020-03-312021-10-07보령제약 주식회사Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물
CN115551518B (zh)*2020-05-072023-10-24上海华禹生物科技有限公司使用n2-喹啉或异喹啉取代的嘌呤衍生物的癌症联合疗法
RU2739125C1 (ru)*2020-06-072020-12-21Государственное бюджетное учреждение здравоохранения города Москвы «Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского Департамента здравоохранения города Москвы» (ГБУЗ "НИИ СП ИМ. Н.В.СКЛИФОСОВСКОГО ДЗМ")Способ лечения лимфоцеле ложа нефротрансплантата после аллогенной трансплантации почки
WO2022044040A1 (en)*2020-08-252022-03-03Msn Laboratories Private Limited, R&D CenterNovel polymorphs of (s)-3-(1-(9h-purin-6-yl-amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2h)-one
WO2022178218A1 (en)2021-02-192022-08-25Mevion Medical Systems, Inc.Gantry for a particle therapy system
WO2023091785A1 (en)*2021-11-222023-05-25Secura Bio, Inc.Methods for treating peripheral t-cell lymphoma
AU2023275778A1 (en)2022-05-252024-12-12Revolution Medicines, Inc.Methods of treating cancer with an mtor inhibitor
WO2024086789A2 (en)*2022-10-202024-04-25Prelude Therapeutics IncorporatedMutant pi3k-alpha inhibitors and their use as pharmaceuticals
WO2024163039A1 (en)2023-01-302024-08-08The Trustees Of Princeton UniversityCancer treatment using pi3k inhibitors in combination with antibiotics or purified diets

Family Cites Families (666)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB812366A (en)1955-08-181959-04-22Wellcome FoundImprovements in and relating to derivatives of pyrimidine and the preparation thereof
GB937725A (en)1960-05-111963-09-25Ciba LtdPyrazolo[3:4-d]pyrimidines
JPS4834699B1 (lt)1968-07-031973-10-23
US3536809A (en)1969-02-171970-10-27Alza CorpMedication method
US3598123A (en)1969-04-011971-08-10Alza CorpBandage for administering drugs
US3657744A (en)1970-05-081972-04-25Univ MinnesotaMethod for fixing prosthetic implants in a living body
DE2139107A1 (de)1971-08-041973-02-15Merck Patent GmbhHeterocyclisch substituierte adenosinverbindungen
US3845770A (en)1972-06-051974-11-05Alza CorpOsmatic dispensing device for releasing beneficial agent
US3916899A (en)1973-04-251975-11-04Alza CorpOsmotic dispensing device with maximum and minimum sizes for the passageway
US3939161A (en)1973-10-291976-02-17Abbott Laboratories1,3-Dimethyl- 1H-pyrazolo(4,3-D) pyrimidine-7 (6H)-ones
US4008719A (en)1976-02-021977-02-22Alza CorporationOsmotic system having laminar arrangement for programming delivery of active agent
US4270537A (en)1979-11-191981-06-02Romaine Richard AAutomatic hypodermic syringe
IT1153216B (it)1981-10-161987-01-14Schering AgProcedimento per la preparazione di composti cianoeterociclici
DE3244594A1 (de)1982-12-021984-06-07Hoechst Ag, 6230 Frankfurt1-phenylisochinolinderivate und verfahren zu ihrer herstellung, diese verbindung enthaltende pharmazeutische praeparate und deren anwendung
DE3406533A1 (de)*1984-02-231985-08-29Boehringer Mannheim Gmbh, 6800 MannheimVerwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US5310731A (en)*1984-06-281994-05-10Whitby Research, Inc.N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
KR890002631B1 (ko)1984-10-041989-07-21몬산토 캄파니생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US4795627A (en)1984-10-181989-01-03University Of PittsburghTritium labelled N-mustard type compounds and a process for their production
IE58110B1 (en)1984-10-301993-07-14Elan Corp PlcControlled release powder and process for its preparation
US4656159A (en)1984-10-311987-04-07Georgetown UniversityGalactose-C-6 nitrogen mustard compounds and their uses
JPS61109797A (ja)1984-11-011986-05-28Yuki Gosei Yakuhin Kogyo Kk標識化ヌクレオチドおよび標識化ポリヌクレオチド
US4596556A (en)1985-03-251986-06-24Bioject, Inc.Hypodermic injection apparatus
US4733665C2 (en)1985-11-072002-01-29Expandable Grafts PartnershipExpandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en)1985-12-041991-06-11Conrex Pharmaceutical CorporationTransdermal and trans-membrane delivery of drugs
US5040548A (en)1989-06-011991-08-20Yock Paul GAngioplasty mehtod
US5350395A (en)1986-04-151994-09-27Yock Paul GAngioplasty apparatus facilitating rapid exchanges
US5061273A (en)1989-06-011991-10-29Yock Paul GAngioplasty apparatus facilitating rapid exchanges
CA1283827C (en)1986-12-181991-05-07Giorgio CirelliAppliance for injection of liquid formulations
US4748982A (en)1987-01-061988-06-07Advanced Cardiovascular Systems, Inc.Reinforced balloon dilatation catheter with slitted exchange sleeve and method
GB8704027D0 (en)1987-02-201987-03-25Owen Mumford LtdSyringe needle combination
US4992445A (en)1987-06-121991-02-12American Cyanamid Co.Transdermal delivery of pharmaceuticals
US5001139A (en)1987-06-121991-03-19American Cyanamid CompanyEnchancers for the transdermal flux of nivadipine
US4940460A (en)1987-06-191990-07-10Bioject, Inc.Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en)1987-06-191990-07-17Bioject, Inc.Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en)1987-06-191988-12-13Bioject, Inc.Non-invasive hypodermic injection device
US5339163A (en)1988-03-161994-08-16Canon Kabushiki KaishaAutomatic exposure control device using plural image plane detection areas
US5073543A (en)1988-07-211991-12-17G. D. Searle & Co.Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
WO1990003370A1 (en)1988-09-281990-04-05Microprobe CorporationDERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE
CA1322628C (en)1988-10-041993-10-05Richard A. SchatzExpandable intraluminal graft
FR2638359A1 (fr)1988-11-031990-05-04Tino DaltoGuide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8827305D0 (en)1988-11-231988-12-29British Bio TechnologyCompounds
IT1229203B (it)1989-03-221991-07-25Bioresearch SpaImpiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en)1989-07-071997-12-23Novartis IncSustained release formulations of water soluble peptides.
US5442039A (en)*1989-07-171995-08-15The Dow Chemical CompanyMesogenic polycyanates and thermosets thereof
US5428125A (en)*1989-07-171995-06-27The Dow Chemical CompanyMesogenic polycyanates and thermosets thereof
US6344053B1 (en)1993-12-222002-02-05Medtronic Ave, Inc.Endovascular support device and method
US5674278A (en)1989-08-241997-10-07Arterial Vascular Engineering, Inc.Endovascular support device
US5292331A (en)1989-08-241994-03-08Applied Vascular Engineering, Inc.Endovascular support device
US5674998A (en)*1989-09-151997-10-07Gensia Inc.C-4' modified adenosine kinase inhibitors
US5646128A (en)1989-09-151997-07-08Gensia, Inc.Methods for treating adenosine kinase related conditions
US5763596A (en)*1989-09-151998-06-09Metabasis Therapeutics, Inc.C-4' modified adenosine kinase inhibitors
US5795977A (en)1989-09-151998-08-18Metabasis Therapeutics, Inc.Water soluble adenosine kinase inhibitors
US5721356A (en)1989-09-151998-02-24Gensia, Inc.Orally active adenosine kinase inhibitors
US5763597A (en)1989-09-151998-06-09Metabasis Therapeutics, Inc.Orally active adenosine kinase inhibitors
US5120548A (en)1989-11-071992-06-09Merck & Co., Inc.Swelling modulated polymeric drug delivery device
US5312335A (en)1989-11-091994-05-17Bioject Inc.Needleless hypodermic injection device
US5064413A (en)1989-11-091991-11-12Bioject, Inc.Needleless hypodermic injection device
EP0507863A4 (en)1989-12-281993-07-07Virginia Commonwealth UniversitySigma receptor ligands and the use thereof
JPH04211063A (ja)1990-03-051992-08-03Takeda Chem Ind Ltd縮合三環性複素環化合物、その製造法、用途及び中間体
GB9009542D0 (en)1990-04-271990-06-20Beecham Group PlcNovel compounds
US5733566A (en)1990-05-151998-03-31Alkermes Controlled Therapeutics Inc. IiControlled release of antiparasitic agents in animals
GB9113137D0 (en)*1990-07-131991-08-07Ici PlcThioxo heterocycles
US5563257A (en)*1990-08-201996-10-08Boehringer Mannheim GmbhPhospholipid derivatives of nucleosides
DE4026265A1 (de)*1990-08-201992-02-27Boehringer Mannheim GmbhNeue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US5190521A (en)1990-08-221993-03-02Tecnol Medical Products, Inc.Apparatus and method for raising a skin wheal and anesthetizing skin
CA2092305C (en)*1990-09-252003-02-11Alfred P. SpadaCompounds having antihypertensive and anti-ischemic properties
US5652366A (en)*1990-09-251997-07-29Rhone-Poulenc Rorer Pharmaceuticals Inc.DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
US5561134A (en)*1990-09-251996-10-01Rhone-Poulenc Rorer Pharmaceuticals Inc.Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5527288A (en)1990-12-131996-06-18Elan Medical Technologies LimitedIntradermal drug delivery device and method for intradermal delivery of drugs
GB9103839D0 (en)1991-02-231991-04-10Smithkline Beecham PlcPharmaceuticals
US5480883A (en)1991-05-101996-01-02Rhone-Poulenc Rorer Pharmaceuticals Inc.Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en)1991-05-102002-04-09Aventis Pharmacetical Products, Inc.Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US6645969B1 (en)1991-05-102003-11-11Aventis Pharmaceuticals Inc.Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en)1991-05-101998-01-20Rhone-Poulenc Rorer Pharmaceuticals Inc.Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0584222B1 (en)1991-05-101997-10-08Rhone-Poulenc Rorer International (Holdings) Inc.Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en)1991-05-101998-02-24Rhone-Poulenc Rorer Pharmaceuticals Inc.Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5714493A (en)1991-05-101998-02-03Rhone-Poulenc Rorer Pharmaceuticals, Inc.Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
GB9118204D0 (en)1991-08-231991-10-09Weston Terence ENeedle-less injector
SE9102652D0 (sv)1991-09-131991-09-13Kabi Pharmacia AbInjection needle arrangement
US5580578A (en)1992-01-271996-12-03Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5916891A (en)*1992-01-131999-06-29Smithkline Beecham CorporationPyrimidinyl imidazoles
IL104369A0 (en)*1992-01-131993-05-13Smithkline Beecham CorpNovel compounds and compositions
DE4204032A1 (de)1992-02-121993-08-19Boehringer Mannheim GmbhNeue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
DE4204031A1 (de)1992-02-121993-08-19Boehringer Mannheim GmbhNeue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel
US5328483A (en)1992-02-271994-07-12Jacoby Richard MIntradermal injection device with medication and needle guard
WO1993018035A1 (en)1992-03-041993-09-16Abbott LaboratoriesAngiotensin ii receptor antagonists
JP2737518B2 (ja)1992-03-161998-04-08富士通株式会社赤外線検知器の冷却構造
US5294612A (en)1992-03-301994-03-15Sterling Winthrop Inc.6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
DE69333580D1 (de)1992-04-072004-09-09Univ MichiganImmunregulation über die cd28-route
GB9208135D0 (en)1992-04-131992-05-27Ludwig Inst Cancer ResPolypeptides having kinase activity,their preparation and use
DE69333955D1 (de)1992-04-242006-02-02Stanford Res Inst IntTargeting homologer sequenzen in eukaryotenzellen
AU669548B2 (en)1992-06-191996-06-13Honeywell Inc.Infrared camera with thermoelectric temperature stabilization
US5383851A (en)1992-07-241995-01-24Bioject Inc.Needleless hypodermic injection device
US6057305A (en)*1992-08-052000-05-02Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech RepublicAntiretroviral enantiomeric nucleotide analogs
US5569189A (en)1992-09-281996-10-29Equidyne Systems, Inc.hypodermic jet injector
US5334144A (en)1992-10-301994-08-02Becton, Dickinson And CompanySingle use disposable needleless injector
TW333456B (en)1992-12-071998-06-11Takeda Pharm Ind Co LtdA pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
TW444018B (en)*1992-12-172001-07-01PfizerPyrazolopyrimidines
US5455258A (en)1993-01-061995-10-03Ciba-Geigy CorporationArylsulfonamido-substituted hydroxamic acids
US5591767A (en)1993-01-251997-01-07Pharmetrix CorporationLiquid reservoir transdermal patch for the administration of ketorolac
IL108523A0 (en)1993-02-031994-05-30Gensia IncPharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
WO1994018215A1 (en)*1993-02-031994-08-18Gensia, Inc.Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
GB9308957D0 (en)1993-04-301993-06-16Cancer Res Campaign TechNovel produgs
AU7052194A (en)1993-06-041995-01-03Regents Of The University Of Michigan, TheMethods for selectively stimulating proliferation of t cells
US6087324A (en)1993-06-242000-07-11Takeda Chemical Industries, Ltd.Sustained-release preparation
US5504103A (en)1993-08-251996-04-02Eli Lilly And CompanyInhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5525503A (en)*1993-09-281996-06-11Dana-Farber Cancer Institute, Inc.Signal transduction via CD28
WO1995012588A1 (en)1993-11-051995-05-11Biochem Pharma Inc.Antineoplastic heteronaphthoquinones
US5656643A (en)1993-11-081997-08-12Rhone-Poulenc Rorer Pharmaceuticals Inc.Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL112249A (en)*1994-01-252001-11-25Warner Lambert CoPharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en)*1994-01-251997-10-21Warner-Lambert CompanyTricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1995024176A1 (en)1994-03-071995-09-14Bioject, Inc.Ampule filling device
US5466220A (en)1994-03-081995-11-14Bioject, Inc.Drug vial mixing and transfer device
US6632789B1 (en)*1994-04-292003-10-14The United States Of America As Represented By The Secretary Of The NavyMethods for modulating T cell responses by manipulating intracellular signal transduction
DE4418690A1 (de)1994-05-281996-01-11Boehringer Mannheim GmbhNeue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
IT1270594B (it)1994-07-071997-05-07Recordati Chem PharmComposizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6323201B1 (en)1994-12-292001-11-27The Regents Of The University Of CaliforniaCompounds for inhibition of ceramide-mediated signal transduction
US5599302A (en)1995-01-091997-02-04Medi-Ject CorporationMedical injection system and method, gas spring thereof and launching device using gas spring
US5863949A (en)1995-03-081999-01-26Pfizer IncArylsulfonylamino hydroxamic acid derivatives
ES2150113T3 (es)1995-04-032000-11-16Novartis AgDerivados de pirazol y procedimientos para la preparacion de los mismos.
US6312894B1 (en)1995-04-032001-11-06Epoch Pharmaceuticals, Inc.Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders
JP3053222B2 (ja)1995-04-202000-06-19ファイザー・インコーポレーテッドMmpおよびtnf抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
US5977061A (en)*1995-04-211999-11-02Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech RepublicN6 - substituted nucleotide analagues and their use
JPH08295667A (ja)1995-04-271996-11-12Takeda Chem Ind Ltd複素環化合物、その製造法および剤
US5593997A (en)1995-05-231997-01-14Pfizer Inc.4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
WO1996037777A1 (en)1995-05-231996-11-28Nelson Randall WMass spectrometric immunoassay
US5730723A (en)1995-10-101998-03-24Visionary Medical Products Corporation, Inc.Gas pressured needle-less injection device and method
US6403599B1 (en)1995-11-082002-06-11Pfizer IncCorticotropin releasing factor antagonists
AU5982296A (en)*1995-06-071996-12-30G.D. Searle & Co.Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone
US5665721A (en)1995-06-071997-09-09Abbott LaboratoriesHeterocyclic substituted cyclopentane compounds
AU6158096A (en)*1995-06-071996-12-30G.D. Searle & Co.Spironolactone and angiotensin ii antagonist combination the rapy for treatment of congestive heart failure
NZ310730A (en)*1995-06-072001-01-26GEpoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure
DE69632684T2 (de)1995-06-272005-06-09Takeda Pharmaceutical Co. Ltd.Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en)1995-09-042001-08-01Takeda Chemical Industries LtdMethod of production of sustained-release preparation
JP2909418B2 (ja)1995-09-181999-06-23株式会社資生堂薬物の遅延放出型マイクロスフイア
US5763885A (en)1995-12-191998-06-09Loral Infrared & Imaging Systems, Inc.Method and apparatus for thermal gradient stabilization of microbolometer focal plane arrays
JPH09143163A (ja)1995-11-291997-06-03Fuji Photo Film Co Ltd含窒素ヘテロ芳香族アミド類の製造方法
ATE225343T1 (de)1995-12-202002-10-15Hoffmann La RocheMatrix-metalloprotease inhibitoren
US5893397A (en)1996-01-121999-04-13Bioject Inc.Medication vial/syringe liquid-transfer apparatus
US5980945A (en)1996-01-161999-11-09Societe De Conseils De Recherches Et D'applications Scientifique S.A.Sustained release drug formulations
US5747235A (en)*1996-01-261998-05-05Eastman Kodak CompanySilver halide light sensitive emulsion layer having enhanced photographic sensitivity
CH690773A5 (de)1996-02-012001-01-15Novartis AgPyrrolo(2,3-d)pyrimide und ihre Verwendung.
DE19603576A1 (de)1996-02-011997-08-07Bayer AgAcylierte 4-Amino und 4-Hydrazinopyrimidine
GB2310952B (en)1996-03-051998-08-19Mitsubishi Electric CorpInfrared detector
GB9607549D0 (en)1996-04-111996-06-12Weston Medical LtdSpring-powered dispensing device
ES2184960T3 (es)1996-05-152003-04-16PfizerNuevas pirimidin-4-onas-(5,6)-heteroaril condensadas 2,3 disustituidas.
GB9611460D0 (en)1996-06-011996-08-07Ludwig Inst Cancer ResNovel lipid kinase
KR20000022040A (ko)*1996-06-202000-04-25보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템약학적 활성 제제를 제공하기 위한 화합물, 방법 및 그의 용도
US6264970B1 (en)1996-06-262001-07-24Takeda Chemical Industries, Ltd.Sustained-release preparation
EP0818442A3 (en)1996-07-121998-12-30Pfizer Inc.Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
ES2175415T3 (es)1996-07-182002-11-16PfizerInhibidores de metaloproteasas matriciales basados en fosfinato.
EA199900139A1 (ru)1996-08-231999-08-26Пфайзер, Инк.Производные арилсульфониламиногидроксамовой кислоты
US6419961B1 (en)1996-08-292002-07-16Takeda Chemical Industries, Ltd.Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en)1996-10-091998-04-09Sumitomo Pharmaceuticals Co., Ltd.Sustained release formulation
US6342514B1 (en)*1996-10-232002-01-29Zymogenetics, Inc.Compositions and methods for treating bone deficit conditions
US5994358A (en)*1996-10-231999-11-30Zymogenetics, Inc.Compositions and methods for treating bone deficit conditions
US5922753A (en)*1996-10-231999-07-13Zymogenetics, Inc.Methods for treating bone deficit conditions with benzothiazole
US5948776A (en)*1996-10-231999-09-07Zymogenetic, Inc.Compositions and methods for treating bone deficit conditions
US5919808A (en)*1996-10-231999-07-06Zymogenetics, Inc.Compositions and methods for treating bone deficit conditions
US6153631A (en)*1996-10-232000-11-28Zymogenetics, Inc.Compositions and methods for treating bone deficit conditions
US5990169A (en)*1996-10-231999-11-23Zymogenetics, Inc.Compositions and methods for treating bone deficit conditions
US5965573A (en)*1996-10-231999-10-12Zymogenetics, Inc.Compositions and methods for treating bone deficit conditions
US6251901B1 (en)*1996-10-232001-06-26Zymogenetics, Inc.Compositions and methods for treating bone deficit conditions
DE69730093T2 (de)1996-10-312006-07-20Takeda Pharmaceutical Co. Ltd.Zubereitung mit verzögerter Freisetzung
US5858753A (en)1996-11-251999-01-12Icos CorporationLipid kinase
EP0942925B1 (en)*1996-12-062006-11-22Vertex Pharmaceuticals IncorporatedInhibitors of interleukin-1 beta converting enzyme
US6197350B1 (en)1996-12-202001-03-06Takeda Chemical Industries, Ltd.Method of producing a sustained-release preparation
US6093737A (en)*1996-12-302000-07-25Merck & Co., Inc.Inhibitors of farnesyl-protein transferase
US6077864A (en)1997-01-062000-06-20Pfizer Inc.Cyclic sulfone derivatives
JPH10206995A (ja)1997-01-211998-08-07Konica Corpハロゲン化銀写真感光材料
US5891474A (en)1997-01-291999-04-06Poli Industria Chimica, S.P.A.Time-specific controlled release dosage formulations and method of preparing same
KR100317146B1 (ko)1997-02-032001-12-22데이비드 존 우드아릴술포닐아미노 히드록삼산 유도체
JP2000507975A (ja)1997-02-072000-06-27ファイザー・インクN−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
US6390821B1 (en)1997-02-072002-05-21Princeton UniversityEngineered protein kinases which can utilize modified nucleotide triphosphate substrates
AU722784B2 (en)1997-02-112000-08-10Pfizer Inc.Arylsulfonyl hydroxamic acid derivatives
HUP0001507A3 (en)1997-03-192002-01-28Abbott Gmbh & Co KgPyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
US7863444B2 (en)1997-03-192011-01-04Abbott Laboratories4-aminopyrrolopyrimidines as kinase inhibitors
US5993412A (en)1997-05-191999-11-30Bioject, Inc.Injection apparatus
WO1998052611A1 (fr)1997-05-231998-11-26Nippon Shinyaku Co., Ltd.Preparation medicamenteuse aux fins de la prevention et du traitement des hepatopathies
US6207679B1 (en)1997-06-192001-03-27Sepracor, Inc.Antimicrobial agents uses and compositions related thereto
EP1003720B1 (en)1997-08-082004-03-31Pfizer Products Inc.Aryloxyarylsulfonylamino hydroxamic acid derivatives
WO1999018077A1 (fr)*1997-10-021999-04-15Eisai Co., Ltd.Derives de pyridine condenses
US6649631B1 (en)*1997-10-232003-11-18The Board Of Regents Of The University Of Texas SystemCompositions and methods for treating bone deficit conditions
EP1043324B1 (en)*1997-11-122004-06-16Mitsubishi Chemical CorporationPurine derivatives and medicine containing the same as the active ingredient
GB9725782D0 (en)1997-12-051998-02-04Pfizer LtdTherapeutic agents
IT1298087B1 (it)1998-01-081999-12-20Fiderm S R LDispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6191170B1 (en)*1998-01-132001-02-20Tularik Inc.Benzenesulfonamides and benzamides as therapeutic agents
GB9801690D0 (en)1998-01-271998-03-25Pfizer LtdTherapeutic agents
CA2322311C (en)1998-03-042009-10-13Bristol-Myers Squibb CompanyHeterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
US6613358B2 (en)1998-03-182003-09-02Theodore W. RandolphSustained-release composition including amorphous polymer
JP4462654B2 (ja)1998-03-262010-05-12ソニー株式会社映像素材選択装置及び映像素材選択方法
US7715989B2 (en)1998-04-032010-05-11Elitech Holding B.V.Systems and methods for predicting oligonucleotide melting temperature (TmS)
US6127121A (en)1998-04-032000-10-03Epoch Pharmaceuticals, Inc.Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
US6432970B2 (en)1998-04-092002-08-13Johns Hopkins University School Of MedicineInhibitors of hedgehog signaling pathways, compositions and uses related thereto
PA8469501A1 (es)1998-04-102000-09-29Pfizer Prod IncHidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es)1998-04-102000-05-24Pfizer Prod IncDerivados biciclicos del acido hidroxamico
KR19990085365A (ko)1998-05-161999-12-06허영섭지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
JP2000072773A (ja)1998-08-282000-03-07Zeria Pharmaceut Co Ltdプリン誘導体
CZ2001959A3 (cs)1998-09-182001-12-12Basf Aktiengesellschaft4-Aminopyrrolopyrimidiny jako inhibitory kinasy
US6362216B1 (en)1998-10-272002-03-26Array Biopharma Inc.Compounds which inhibit tryptase activity
US6114361A (en)1998-11-052000-09-05Pfizer Inc.5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
ES2206191T3 (es)1999-01-112004-05-16Princeton UniversityInhibidores de alta afinidad para validacion de dianas y usos de los mismos.
CZ27399A3 (cs)1999-01-262000-08-16Ústav Experimentální Botaniky Av ČrSubstituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
MXPA01008440A (es)1999-02-222002-04-24Boehringer Ingelheim PharmaDerivados heterociclicos policiclos como agentes anti-inflamatorios..
US6248363B1 (en)1999-11-232001-06-19Lipocine, Inc.Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
HK1043127B (zh)1999-03-122004-12-24贝林格尔‧英格海姆药物公司作为消炎剂的化合物
EP1040831A3 (en)*1999-04-022003-05-02Pfizer Products Inc.Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
SE515856C2 (sv)1999-05-192001-10-22Ericsson Telefon Ab L MBärare för elektronikkomponenter
CA2375734A1 (en)1999-06-032000-12-14Knoll GmbhBenzothiazinone and benzoxazinone compounds
US6387894B1 (en)*1999-06-112002-05-14Pfizer Inc.Use of CRF antagonists and renin-angiotensin system inhibitors
TWI262914B (en)1999-07-022006-10-01Agouron PharmaCompounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es)1999-07-022001-03-29Agouron PharmaCompuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1081137A1 (en)1999-08-122001-03-07Pfizer Products Inc.Selective inhibitors of aggrecanase in osteoarthritis treatment
GB9919588D0 (en)*1999-08-181999-10-20Hoechst Schering Agrevo GmbhFungicidal compounds
AU7080500A (en)1999-08-272001-03-26Chemocentryx, Inc.Compounds and methods for modulating cxcr3 function
US20070021493A1 (en)1999-09-162007-01-25Curis, Inc.Mediators of hedgehog signaling pathways, compositions and uses related thereto
ATE286033T1 (de)1999-09-162005-01-15Curis IncVermittler von igel signalwegen, deren zusammenstellungen und verwendungen
US6921763B2 (en)1999-09-172005-07-26Abbott LaboratoriesPyrazolopyrimidines as therapeutic agents
US6660744B1 (en)1999-09-172003-12-09Abbott Gmbh & Co. KgPyrazolopyrimidines as therapeutic agents
WO2001021160A2 (en)1999-09-232001-03-29Axxima Pharmaceuticals AktiengesellschaftCarboxymide and aniline derivatives as selective inhibitors of pathogens
US6506769B2 (en)*1999-10-062003-01-14Boehringer Ingelheim Pharmaceuticals, Inc.Heterocyclic compounds useful as inhibitors of tyrosine kinases
ES2225231T3 (es)1999-10-062005-03-16Boehringer Ingelheim Pharmaceuticals Inc.Compuestos heterociclicos, utiles como inhibidores de tirosina quinasas.
AU7683500A (en)1999-10-122001-04-23Takeda Chemical Industries Ltd.Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
EP1728797A3 (en)1999-10-132011-03-02Johns Hopkins University School of MedicineRegulators of the hedgehog pathway, compositions and uses related thereto
CA2286451A1 (en)1999-10-142001-04-14Grant A. MitchellHormone-sensitive lipase mediated male infertility
US6472153B1 (en)1999-10-262002-10-29Epoch Biosciences, Inc.Hybridization-triggered fluorescent detection of nucleic acids
EP1095933A1 (en)1999-10-302001-05-02Aventis Pharma Deutschland GmbHNovel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
US6660845B1 (en)1999-11-232003-12-09Epoch Biosciences, Inc.Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
IL133809A0 (en)1999-12-302001-04-30Yeda Res & DevSteroidal alkaloids and pharmaceutical compositions comprising them
GB0002032D0 (en)2000-01-282000-03-22Zeneca LtdChemical compounds
US7217722B2 (en)2000-02-012007-05-15Kirin Beer Kabushiki KaishaNitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
FR2804958B1 (fr)2000-02-152005-07-08Hoechst Marion Roussel IncDerives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
EP1272168B2 (en)2000-03-302009-10-28Curis, Inc.Small organic molecule regulators of cell proliferation
US7115653B2 (en)2000-03-302006-10-03Curis, Inc.Small organic molecule regulators of cell proliferation
US6613798B1 (en)2000-03-302003-09-02Curis, Inc.Small organic molecule regulators of cell proliferation
US20020127625A1 (en)2000-03-312002-09-12Forskarpatent Is Syd AbMethods of diagnosing immune related diseases
CA2406278C (en)*2000-04-252012-06-05Icos CorporationInhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en)*2000-04-252003-12-23Icos CorporationInhibitors of human phosphatidylinositol 3-kinase delta
WO2001091699A2 (en)*2000-05-302001-12-06Advanced Research & Technology InstituteCompositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
US6667398B2 (en)2000-06-222003-12-23Pfizer IncProcess for the preparation of pyrazolopyrimidinones
IL153119A0 (en)*2000-06-272003-06-24Genelabs Tech IncNovel compounds possessing antibacterial, antifungal or antitumor activity
US6534691B2 (en)2000-07-182003-03-18E. I. Du Pont De Nemours And CompanyManufacturing process for α-olefins
WO2002028853A1 (en)*2000-10-022002-04-11Tanabe Seiyaku Co., Ltd.Benzylamine compound, process for producing the same, and intermediate therefor
WO2002030358A2 (en)*2000-10-112002-04-18Tularik Inc.Modulation of ccr4 function
JP4741170B2 (ja)2000-10-112011-08-03アプライド バイオシステムズ リミテッド ライアビリティー カンパニーアニオン性リンカーを有する蛍光核酸塩基結合体
FR2815346B1 (fr)2000-10-132004-02-20Servier LabNouveaux composes aminotriazolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2002131859A (ja)2000-10-192002-05-09Konica Corp撮影用赤外感光性ハロゲン化銀写真感光材料及び赤外感光性ハロゲン化銀乳剤
US6890747B2 (en)2000-10-232005-05-10Warner-Lambert CompanyPhosphoinositide 3-kinases
BR0116096A (pt)2000-12-112005-10-18Tularik IncComposto, composição farmacêutica, e, métodos para tratar uma condição ou doença inflamatória ou imune em um paciente, para tratar uma condição ou doença mediada por cxcr3 em um paciente, e para a modulação da função de cxcr3 em uma célula
AU2002219555B2 (en)*2000-12-282006-11-30Daiichi Pharmaceutical Co., Ltd.VLA-4 Inhibitors
EP1353674A1 (en)2000-12-292003-10-22Alteon, Inc.Method for treating glaucoma ivb
AU2002232919A1 (en)2000-12-292002-07-16Alteon, Inc.Method for treating fibrotic diseases or other indications
US7105499B2 (en)2001-01-222006-09-12Merck & Co., Inc.Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
NZ526703A (en)2001-01-222004-12-24Merck & Co IncNucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0102239D0 (en)2001-01-292001-03-14Cancer Res Ventures LtdMethods of chemical synthisis
PA8539501A1 (es)2001-02-142002-09-30Warner Lambert CoCompuestos triazolo como inhibidores de mmp
PA8539401A1 (es)2001-02-142002-10-28Warner Lambert CoQuinazolinas como inhibidores de mmp-13
MXPA03008560A (es)2001-03-222004-06-30Abbot Gmbh & Co KgPirazolopirimidinas como agentes terapeuticos.
WO2002088025A1 (en)2001-04-262002-11-07New York UniversityMethod for dissolving carbon nanotubes
DE60218458T2 (de)2001-05-082007-11-15Kudos Pharmaceuticals Ltd.Isochinolinon derivate als parp inhibitoren
IL149462A0 (en)2001-05-092002-11-10Warner Lambert CoMethod of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
WO2002094264A1 (en)*2001-05-232002-11-28Tularik Inc.Ccr4 antagonists
EP1401817A4 (en)*2001-06-132005-11-02Genesoft Pharmaceuticals Inc ISOQUINOLINE COMPOUNDS WITH ANTI-INFECTIOUS ACTIVITY
EP1470119A4 (en)2001-06-132005-10-19Genesoft Pharmaceuticals Inc BENZOTHIOPHENE COMPOUNDS WITH ANTI-INFECTIOUS ACTIVITY
US20030236198A1 (en)2001-06-132003-12-25Genesoft, Inc.Antipathogenic benzamide compounds
US20030114467A1 (en)2001-06-212003-06-19Shakespeare William C.Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
DE10134721A1 (de)2001-07-172003-02-06Bayer AgTetrahydrochinoxaline
EA007339B1 (ru)2001-07-272006-08-25Кьюэрис, Инк.Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ
DE60216115T2 (de)*2001-08-012007-05-31Merck & Co., Inc.BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
AU2002327422A1 (en)2001-08-032003-03-18Abbott LaboratoriesMethod of identifying inhibitors of lck
DE15187654T1 (de)2001-08-102016-12-01Shionogi & Co., LtdAntivirales Mittel
JP2003073357A (ja)2001-09-032003-03-12Mitsubishi Pharma Corpアミド化合物を含有するRhoキナーゼ阻害剤
EP1572072A4 (en)*2001-09-132009-04-01Genesoft Inc PROCESS FOR TREATING INFECTIONS WITH PHARMACORESISTANT BACTERIA
US7101884B2 (en)2001-09-142006-09-05Merck & Co., Inc.Tyrosine kinase inhibitors
AUPR769501A0 (en)2001-09-142001-10-11Biomolecular Research Institute LimitedCytokine receptor 1
US8124625B2 (en)2001-09-142012-02-28Shionogi & Co., Ltd.Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7269663B2 (en)2001-09-282007-09-11Intel CorporationTagging packets with a lookup key to facilitate usage of a unified packet forwarding cache
TWI330183B (lt)2001-10-222010-09-11Eisai R&D Man Co Ltd
HUP0402106A3 (en)2001-11-012009-07-28Janssen Pharmaceutica NvHeteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
CN1612733A (zh)2001-11-092005-05-04贝林格尔·英格海姆药物公司用作蛋白激酶抑制剂的苯并咪唑类
DE10159269A1 (de)2001-12-032003-06-18Bayer AgArylierung von Olefinen
DE10159270A1 (de)2001-12-032003-06-12Bayer AgVerfahren zur Arylierung von Olefinen
WO2003048081A2 (en)2001-12-042003-06-12Bristol-Myers Squibb CompanyGlycinamides as factor xa inhibitors
EP1465869B1 (en)2001-12-212013-05-15Exelixis Patent Company LLCModulators of lxr
JP4085237B2 (ja)*2001-12-212008-05-14日本電気株式会社携帯電話の利用契約システムと通信方法
US7064218B2 (en)*2001-12-262006-06-20Genelabs Technologies, Inc.Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity
US7414036B2 (en)2002-01-252008-08-19Muscagen LimitedCompounds useful as A3 adenosine receptor agonists
US20040043959A1 (en)2002-03-042004-03-04Bloom Laura A.Combination therapies for treating methylthioadenosine phosphorylase deficient cells
WO2003082341A1 (en)2002-03-222003-10-09Cellular Genomics, Inc.AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO[3,4-d] PYRIMIDINES AS KINASE MODULATORS
AU2003219088A1 (en)2002-03-262003-10-08Zentopharm GmbhFredericamycin derivatives
US7166293B2 (en)2002-03-292007-01-23Carlsbad Technology, Inc.Angiogenesis inhibitors
DE10217046A1 (de)2002-04-172003-11-06Bioleads GmbhFredericamycin-Derivate
AU2003231032B2 (en)2002-04-222008-07-10Johns Hopkins University School Of MedicineModulators of hedgehog signaling pathways, compositions and uses related thereto
CA2483500A1 (en)*2002-04-262003-11-06Pfizer Products Inc.Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
US6794562B2 (en)2002-05-012004-09-21Stine Seed Farm, Inc.Soybean cultivar 0332143
AU2003299517A1 (en)2002-05-232004-05-25Merck & Co., Inc.Mitotic kinesin inhibitors
JP2005538062A (ja)*2002-06-142005-12-15サイトキネティクス・インコーポレーテッド化合物、組成物、および方法
US7265111B2 (en)*2002-06-272007-09-04Sanofi-Aventis Deutschland GmbhAdenosine analogues and their use as pharmaceutical agents
KR101124245B1 (ko)2002-06-272012-07-02노보 노르디스크 에이/에스치료제로서 아릴 카르보닐 유도체
WO2004002481A1 (en)2002-06-272004-01-08Novo Nordisk A/SAryl carbonyl derivatives as therapeutic agents
DE10230917A1 (de)2002-07-092004-02-05Bioleads GmbhFredericamycin-Derivate
WO2004006906A2 (en)2002-07-152004-01-22Combinatorx, IncorporatedMethods for the treatment of neoplasms
EP1394159A1 (fr)2002-08-132004-03-03Warner-Lambert Company LLCNouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP1539163A1 (en)*2002-08-132005-06-15Warner-Lambert Company LLC4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
NZ538420A (en)*2002-08-162007-06-29Kinacia Pty LtdInhibition of phosphoinositide 3-kinase beta
CN101260104A (zh)*2002-08-162008-09-10阿斯利康(瑞典)有限公司抑制磷酸肌醇3-激酶β
JP2005536553A (ja)2002-08-212005-12-02サイトキネティクス・インコーポレーテッド化合物、組成物および方法
US20030139427A1 (en)2002-08-232003-07-24Osi Pharmaceuticals Inc.Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004020599A2 (en)2002-08-292004-03-11Curis, Inc.Hedgehog antagonists, methods and uses related thereto
GB0220319D0 (en)2002-09-022002-10-09Cancer Res Campaign TechEnzyme activated self-immolative nitrogen mustard drugs
AU2003266668A1 (en)2002-09-302004-04-23Banyu Pharmaceutical Co., Ltd.2-aminobenzimidazole derivative
EP1549614A4 (en)2002-10-032008-04-16Targegen Inc VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
US20050282814A1 (en)2002-10-032005-12-22Targegen, Inc.Vasculostatic agents and methods of use thereof
US20040146941A1 (en)2002-11-042004-07-29Biliang ZhangChemical encoding technology for combinatorial synthesis
JP2004161716A (ja)2002-11-152004-06-10Takeda Chem Ind LtdJnk阻害剤
WO2004046128A1 (en)2002-11-212004-06-03Vicore Pharma AbNew bicyclic angiotensin ii agonists
EP1572660B1 (en)2002-12-202011-01-26X-Ceptor Therapeutics, Inc.Isoquinolinone derivatives and their use as therapeutic agents
US7365094B2 (en)*2002-12-232008-04-294Sc AgCompounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7247736B2 (en)2002-12-232007-07-244Sc AgMethod of identifying inhibitors of DHODH
US7071355B2 (en)*2002-12-232006-07-044 Sc AgCompounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
FR2850022B1 (fr)2003-01-222006-09-08Centre Nat Rech ScientNouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
WO2004075917A1 (ja)2003-02-282004-09-10Toudai Tlo, Ltd.器官または組織の線維化抑制剤
KR20050106081A (ko)2003-03-062005-11-08디에스엠 아이피 어셋츠 비.브이.α-아미노 카보닐 화합물의 제조방법
TW200505902A (en)2003-03-202005-02-16Schering CorpCannabinoid receptor ligands
KR20050122220A (ko)2003-03-252005-12-28다케다 샌디에고, 인코포레이티드디펩티딜 펩티다제 억제제
GB0306907D0 (en)2003-03-262003-04-30Angiogene Pharm LtdBoireductively-activated prodrugs
WO2004087679A1 (en)2003-04-012004-10-14Aponetics Ag2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
WO2004089297A2 (en)2003-04-022004-10-21Suntory Pharmaceutical Research Laboratories, LlcCompounds and methods for treatment of thrombosis
WO2004089877A1 (en)2003-04-142004-10-21Astrazeneca AbNew hydroxynaphthyl amides
EP1479675A1 (en)2003-05-192004-11-24Aventis Pharma Deutschland GmbHIndazole-derivatives as factor Xa inhibitors
US7317027B2 (en)2003-05-192008-01-08Sanofi-Aventis Deutschland GmbhAzaindole-derivatives as factor Xa inhibitors
US7223780B2 (en)2003-05-192007-05-29Sanofi-Aventis Deutschland GmbhTriazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1646615B1 (en)2003-06-062009-08-26Vertex Pharmaceuticals IncorporatedPyrimidine derivatives as modulators of atp-binding cassette transporters
US7429596B2 (en)2003-06-202008-09-30The Regents Of The University Of California1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
CA2572324A1 (en)2003-07-022005-01-13Warner-Lambert Company LlcCombination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
US20080118493A1 (en)2003-07-152008-05-22Beachy Philip AElevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity
GB0317951D0 (en)2003-07-312003-09-03Trigen LtdCompounds
WO2005014532A1 (en)2003-08-082005-02-17Transtech Pharma, Inc.Aryl and heteroaryl compounds, compositions and methods of use
US7208601B2 (en)2003-08-082007-04-24Mjalli Adnan M MAryl and heteroaryl compounds, compositions, and methods of use
US20050043239A1 (en)2003-08-142005-02-24Jason DouangpanyaMethods of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en)2003-08-142005-02-24Icos CorporationMethods of inhibiting leukocyte accumulation
MXPA06001758A (es)2003-08-152006-08-11Irm LlcAnilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
US7390820B2 (en)2003-08-252008-06-24Amgen Inc.Substituted quinolinone derivatives and methods of use
WO2005044181A2 (en)2003-09-092005-05-19Temple University-Of The Commonwealth System Of Higher EducationProtection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
GB0322409D0 (en)2003-09-252003-10-29Astrazeneca AbQuinazoline derivatives
US8067608B2 (en)2003-09-292011-11-29The Johns Hopkins UniversityHedgehog pathway antagonists
WO2005032343A2 (en)2003-10-012005-04-14The Johns Hopkins UniversityHedgehog signaling in prostate regeneration neoplasia and metastasis
US20080057071A1 (en)2003-10-202008-03-06Watkins David NUse Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
TWI344364B (en)2003-11-102011-07-01Synta Pharmaceuticals CorpFused heterocyclic compounds
JP2007511596A (ja)2003-11-172007-05-10ファイザー・プロダクツ・インク癌の治療において有用なピロロピリミジン化合物
WO2005054202A1 (en)*2003-11-252005-06-16Eli Lilly And Company7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
WO2005061460A1 (en)2003-12-082005-07-07Cytokinetics, Inc.Compounds, compositions, and methods
EP1715871A1 (en)2003-12-222006-11-02Gilead Sciences, Inc.Kinase inhibitor phosphonate conjugates
CA2548326A1 (en)2003-12-232005-07-14Novartis AgBicyclic heterocyclic p-38 kinase inhibitors
CA2552664A1 (en)*2004-01-082005-07-28Michigan State UniversityMethods for treating and preventing hypertension and hypertension-related disorders
US20050214310A1 (en)2004-01-232005-09-29Seattle Genetics, Inc.Melphalan prodrugs
KR20070039869A (ko)2004-02-032007-04-13브루스 더블유. 스미스용액을 사용한 포토리소그래피 방법 및 관련 시스템
EP1730148A4 (en)2004-02-032009-08-19Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
US7521455B2 (en)*2004-02-132009-04-21Banyu Pharmaceutical Co. Ltd.Fused ring 4-oxopyrimidine derivative
US20050187418A1 (en)2004-02-192005-08-25Small Brooke L.Olefin oligomerization
EP1720874A4 (en)2004-02-242010-03-03Bioaxone Therapeutique Inc 4-SUBSTITUTED PIPERIDINE DERIVATIVES
KR100843526B1 (ko)*2004-02-272008-07-03에프. 호프만-라 로슈 아게피라졸의 접합 유도체
EP1568698A1 (en)2004-02-272005-08-31Aventis Pharma Deutschland GmbHPyrrole-derivatives as factor Xa inhibitors
EP1571154A1 (en)2004-03-032005-09-07Aventis Pharma Deutschland GmbHBeta-aminoacid-derivatives as factor Xa inhibitors
EP2308879A1 (en)2004-04-022011-04-13OSI Pharmaceuticals, Inc.6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
MXPA06012333A (es)2004-04-302007-01-17Takeda PharmaceuticalCompuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13.
KR20070005736A (ko)2004-04-302007-01-10제넨테크, 인크.헤지호그 신호전달 경로의 퀴녹살린 억제제
DE102004022897A1 (de)2004-05-102005-12-08Bayer Cropscience AgAzinyl-imidazoazine
LT1761540T (lt)*2004-05-132017-02-27Icos CorporationChinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
CA2566436C (en)2004-05-132011-05-10Vanderbilt UniversityPhosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
CA2567883A1 (en)2004-05-252005-12-15Icos CorporationMethods for treating and/or preventing aberrant proliferation of hematopoietic cells
CA2569406A1 (en)2004-06-042005-12-22Icos CorporationMethods for treating mast cell disorders
GB0413605D0 (en)2004-06-172004-07-21Addex Pharmaceuticals SaNovel compounds
CN1980911A (zh)2004-07-012007-06-13默克公司有丝分裂驱动蛋白抑制剂
US20060019967A1 (en)2004-07-212006-01-26Su-Ying WuSARS CoV main protease inhibitors
WO2006015279A1 (en)2004-07-282006-02-09Neurogen CorporationHeterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
WO2006026430A2 (en)2004-08-272006-03-09Infinity Pharmaceuticals, Inc.Cyclopamine analogues and methods of use thereof
CA2579002C (en)2004-09-022012-11-27Genentech, Inc.Pyridyl inhibitors of hedgehog signalling
GB0420722D0 (en)2004-09-172004-10-20Addex Pharmaceuticals SaNovel allosteric modulators
WO2006038865A1 (en)2004-10-012006-04-13Betagenon AbNucleotide derivatives for the treatment of type 2 diabetes and other disorders
MX2007005125A (es)2004-10-282007-07-04Irm LlcCompuestos y composiciones como moduladores de la senda de hedgehog.
US7622451B2 (en)2004-11-032009-11-24University Of KansasNovobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
EP1807440B1 (en)2004-11-032020-02-19The University of KansasNovobiocin analogues as anticancer agents
US8212012B2 (en)2004-11-032012-07-03University Of KansasNovobiocin analogues having modified sugar moieties
US8212011B2 (en)2004-11-032012-07-03University Of KansasNovobiocin analogues
GB0425035D0 (en)*2004-11-122004-12-15Novartis AgOrganic compounds
US9512125B2 (en)2004-11-192016-12-06The Regents Of The University Of CaliforniaSubstituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US8946444B2 (en)2004-11-232015-02-03Ptc Therapeutics, Inc.Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
MX2007006109A (es)2004-12-012007-10-04Devgen NvDerivados de tiazol sustituidos en 5-carboxamido que interactuan con canales de iones, en particular con canales ionicos de la familia de kv.
US20060156485A1 (en)2005-01-142006-07-20The Procter & Gamble CompanyKeratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
GB0501999D0 (en)2005-02-012005-03-09Sentinel Oncology LtdPharmaceutical compounds
US20080287469A1 (en)2005-02-172008-11-20Diacovo Thomas GPhosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
US7579348B2 (en)2005-02-252009-08-25Pgxhealth, LlcDerivatives of 8-substituted xanthines
US20090124654A1 (en)2005-03-012009-05-14Mjalli Adnan M MAryl and Heteroaryl Compounds, Compositions, Methods of Use
US7872050B2 (en)2005-03-142011-01-18Yaupon Therapeutics Inc.Stabilized compositions of volatile alkylating agents and methods of using thereof
JP2008536835A (ja)2005-04-062008-09-11アイアールエム・リミテッド・ライアビリティ・カンパニージアリールアミン含有化合物および組成物、ならびにステロイドホルモン核受容体のモジュレータとしてのそれらの使用
KR100781704B1 (ko)2005-04-202007-12-03에스케이케미칼주식회사피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
CA2606399A1 (en)2005-04-252006-11-02Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech RepublicUse of compounds to enhance processivity of telomerase
CN100526315C (zh)2005-06-162009-08-12浙江医药股份有限公司新昌制药厂N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
KR20140026644A (ko)2005-06-222014-03-05케모센트릭스, 인크.아자인다졸 화합물 및 사용방법
MX2007016270A (es)2005-06-272008-03-05Amgen IncCompuestos aril nitrilo anti-inflamatorios.
JP2009500437A (ja)2005-07-112009-01-08デブジェン エヌブイキナーゼ阻害剤としてのアミド誘導体
WO2007006546A1 (en)2005-07-112007-01-18Devgen N.V.Amide derivatives as kinase inhibitors
WO2007029121A2 (en)2005-07-212007-03-15Galderma Research & DevelopmentNovel cyclopent-2-en-1-one derivatives which are ppar receptor modulators, and use thereof in pharmaceutical or cosmetic compositions
US20070017915A1 (en)2005-07-222007-01-25Weder Donald ECollapsible and/or erectable substantially egg-shaped container
US7700552B2 (en)2005-07-292010-04-20Medivir AbMacrocyclic inhibitors of hepatitis C virus
GB0516723D0 (en)2005-08-152005-09-21Novartis AgOrganic compounds
WO2007023110A2 (en)2005-08-252007-03-01F. Hoffmann-La Roche AgP38 map kinase inhibitors and methods for using the same
WO2007025090A2 (en)2005-08-252007-03-01Kalypsys, Inc.Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2007028022A2 (en)2005-09-012007-03-08Renovis, Inc.Novel compounds as p2x7 modulators and uses thereof
WO2007025534A1 (de)2005-09-012007-03-08Bioagency AgFredericamycin-derivate
US20070072897A1 (en)2005-09-292007-03-29WyethPhenylaminopropanol derivatives and methods of their use
FR2892859B1 (fr)2005-10-272008-06-06Commissariat Energie AtomiqueProcede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications
US20090156611A1 (en)2005-11-112009-06-18Licentia Ltd.Mammalian hedgehog signaling modulators
JP5225857B2 (ja)2005-11-142013-07-03ジェネンテック,インコーポレイティドヘッジホッグシグナル伝達のビスアミド阻害剤
KR20080078668A (ko)2005-11-172008-08-27오에스아이 파마슈티컬스, 인코포레이티드융합된 바이사이클릭 mTOR 억제자
JP2009516742A (ja)2005-11-222009-04-23メルク エンド カムパニー インコーポレーテッドインドールオレキシン受容体アンタゴニスト
CA2630920A1 (en)2005-11-222007-05-31University Of South FloridaInhibition of cell proliferation
JP2009520028A (ja)2005-12-192009-05-21オーエスアイ・ファーマスーティカルズ・インコーポレーテッドIgfr抑制剤および抗癌剤の併用
US7572809B2 (en)2005-12-192009-08-11Hoffmann-La Roche Inc.Isoquinoline aminopyrazole derivatives
TW200801008A (en)2005-12-292008-01-01Abbott LabProtein kinase inhibitors
US8053603B2 (en)2006-01-062011-11-08Sunovion Pharmaceuticals Inc.Tetralone-based monoamine reuptake inhibitors
US9540327B2 (en)2006-01-132017-01-10University Of Kentucky Research FoundationBis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors
US20080058521A1 (en)2006-01-262008-03-06WyethProcesses for the preparation of compounds
PE20071025A1 (es)2006-01-312007-10-17Mitsubishi Tanabe Pharma CorpCompuesto amina trisustituido
JP2009529047A (ja)2006-03-072009-08-13アレイ バイオファーマ、インコーポレイテッドヘテロ二環系ピラゾール化合物およびその使用
PL2650305T3 (pl)2006-03-242024-09-16Bioverativ Therapeutics Inc.PC5 jako enzym przetwarzający propeptyd czynnika IX
CA2647543A1 (en)2006-03-292007-11-08Foldrx Pharmaceuticals, Inc.Inhibition of alpha-synuclein toxicity
ES2423010T3 (es)2006-04-042013-09-17The Regents Of The University Of CaliforniaDerivados de pirazolopirimidina para su uso como antagonistas de cinasa
EP2007757B1 (en)2006-04-132012-10-03Vertex Pharmceuticals IncorporatedThiophene-carboxamides useful as inhibitors of protein kinases
JP2009536156A (ja)2006-04-142009-10-08ノバルティス アクチエンゲゼルシャフトヘッジホッグ経路関連障害の処置におけるビアリールカルボキサミドの使用
WO2007121453A2 (en)2006-04-172007-10-25The Regents Of The University Of California2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
PT2013211E (pt)2006-04-212012-06-21Novartis AgDerivados de purina para utilização como agonistas de receptores a2a de adenosina
GB0607948D0 (en)2006-04-212006-05-31Novartis AgOrganic compounds
GB0607950D0 (en)2006-04-212006-05-31Novartis AgOrganic compounds
US20090082370A1 (en)2006-04-252009-03-26Neil Thomas ThompsonPharmaceutical Combinations of PK Inhibitors and Other Active Agents
JP2009536161A (ja)2006-04-252009-10-08アステックス、セラピューティックス、リミテッド医薬化合物
DE102006020327A1 (de)2006-04-272007-12-27Bayer Healthcare AgHeterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
UA93548C2 (uk)2006-05-052011-02-25Айерем ЕлелсіСполуки та композиції як модулятори хеджхогівського сигнального шляху
WO2007135398A1 (en)2006-05-222007-11-29Astrazeneca AbIndole derivatives
GB0610242D0 (en)2006-05-232006-07-05Novartis AgOrganic compounds
GB0610317D0 (en)2006-05-242006-07-05Medical Res CouncilAntiparasitic compounds and compositions
EP1859772B1 (en)2006-05-242010-12-15Guardant S.r.l.Alkalized local anesthetic in bag
WO2008011109A2 (en)2006-07-202008-01-24Amgen Inc.Substituted pyridone compounds and methods of use
CA2657200A1 (en)2006-07-282008-01-31Novartis Ag2,4-substituted quinazolines as lipid kinase inhibitors
US20100216791A1 (en)2006-08-172010-08-26AstrazenecaPyridinylquinazolinamine derivatives and their use as b-raf inhibitors
WO2008023357A1 (en)2006-08-222008-02-28Technion Research And Development Foundation Ltd.Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr)
JP2010501593A (ja)2006-08-242010-01-21セレネックス, インコーポレイテッドイソキノリン、キナゾリンおよびフタラジン誘導体
PL2061765T3 (pl)2006-09-012015-04-30Senhwa Biosciences IncModulatory białkowych kinaz serynowo-treoninowych i PARP
WO2008025755A1 (de)2006-09-012008-03-06Basf SeVerwendung von n-haltigen heterozyklen in dermokosmetika
EP1903044A1 (en)2006-09-142008-03-26Novartis AGAdenosine Derivatives as A2A Receptor Agonists
WO2009019531A2 (en)2006-09-182009-02-12Compugen LtdBioactive peptides and method of using same
EP2298772A1 (en)2006-10-182011-03-23Takeda Pharmaceutical Company LimitedFused heterocyclic compounds
AU2007329678A1 (en)2006-10-312008-06-12Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human ServicesSmoothened polypeptides and methods of use
US7772180B2 (en)2006-11-092010-08-10Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
US20100216820A1 (en)2006-11-132010-08-26White Stephen LThienopyrimidiones for treatment of inflammatory disorders and cancers
RS53335B (en)2006-11-202014-10-31Novartis Ag CRYSTAL MONOTOSYLATE SO 2-METHYL-2- [4- (3-METHYL-2-OXO-8-HINOLIN-3-IL-2,3-Dihydro-imidazo [4,5-C] HINOLIN-1-IL) - Phenyl] -PROPIONITRILA
WO2008063625A2 (en)2006-11-202008-05-29Adolor CorporationPyridine compounds and methods of their use
JP2010512331A (ja)2006-12-062010-04-22ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツンググルココルチコイド模倣薬、それらの製造方法、医薬組成物、及びこれらの使用
BRPI0720546A2 (pt)2006-12-142015-06-23Daiichi Sankyo Co LtdComposto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
WO2008082487A2 (en)2006-12-202008-07-10Schering CorporationNovel jnk inhibitors
ATE553105T1 (de)2006-12-222012-04-15Ind Res LtdAzetidin-analoge ais nucleosidase- und phosphorylase-hemmer
TWI433674B (zh)2006-12-282014-04-11Infinity Discovery Inc環杷明(cyclopamine)類似物類
WO2008094737A2 (en)2007-01-262008-08-07Irm LlcPurine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
US20080200461A1 (en)2007-02-202008-08-21Cropsolution, Inc.Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
AU2008223355B2 (en)2007-03-072014-03-20Infinity Discovery, Inc.Heterocyclic cyclopamine analogs and methods of use thereof
AU2008222655B2 (en)2007-03-072014-03-27Infinity Pharmaceuticals, Inc.Cyclopamine lactam analogs and methods of use thereof
EP2073799A4 (en)2007-03-122009-08-19Vm Discovery Inc NOVEL ACTIVE SUBSTANCES FROM CALCIUMIONAL CHANNEL MODULATORS
CA2680796A1 (en)2007-03-142008-09-18Exelixis, Inc.Inhibitors of the hedgehog pathway
CN101657430B (zh)2007-03-152013-05-01诺瓦提斯公司有机化合物及其用途
PL2137186T3 (pl)2007-03-232016-09-30Związki heterocykliczne i ich zastosowania
JP2010522177A (ja)2007-03-232010-07-01アムジエン・インコーポレーテツド複素環化合物およびその使用
EP2139882B1 (en)*2007-03-232013-12-25Amgen Inc.3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
WO2008117050A1 (en)2007-03-272008-10-02Astrazeneca AbPyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US7867983B2 (en)2007-03-292011-01-11The University Of ConnecticutMethods to protect skeletal muscle against injury
CN101636397B (zh)2007-04-132012-06-13中国人民解放军军事医学科学院毒物药物研究所脲类化合物、其制备方法及其医药用途
AU2008238379A1 (en)2007-04-132008-10-23Sanofi-AventisA transition metal catalyzed synthesis of N-aminoindoles
US20090054517A1 (en)2007-04-202009-02-26Lubahn Dennis BPhytoestrogens As Regulators Of Hedgehog Signaling And Methods Of Their Use In Cancer Treatment
JP2010163361A (ja)2007-04-272010-07-29Dainippon Sumitomo Pharma Co Ltdキノリン誘導体
US7960353B2 (en)2007-05-102011-06-14University Of KansasNovobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US20090214529A9 (en)*2007-05-222009-08-27Taigen Biotechnology Co., Ltd.Kinesin inhibitors
US7928111B2 (en)2007-06-082011-04-19Senomyx, Inc.Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9603848B2 (en)2007-06-082017-03-28Senomyx, Inc.Modulation of chemosensory receptors and ligands associated therewith
WO2008156783A2 (en)2007-06-182008-12-24University Of Louisville Research Foundation, Inc.Family of pfkfb3 inhibitors with anti-neoplastic activities
US8557823B2 (en)2007-06-182013-10-15Advanced Cancer Therapeutics, LlcFamily of PFKFB3 inhibitors with anti-neoplastic activities
US8541593B2 (en)2007-06-212013-09-24Amgen Inc.Process for making substituted 2-amino-thiazolones
CN101772479B (zh)2007-06-222014-07-23北卡罗莱纳州立大学利用二环丙烯化合物抑制植物中乙烯响应的方法
CA2693142A1 (en)2007-06-262008-12-31Sanofi-AventisA regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles
WO2009004621A1 (en)2007-07-022009-01-08Technion Research & Development Foundation Ltd.Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage
RU2345996C1 (ru)2007-07-172009-02-10Андрей Александрович ИващенкоАннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
JP4834699B2 (ja)2007-07-302011-12-14田辺三菱製薬株式会社医薬組成物
JP4846769B2 (ja)2007-07-302011-12-28田辺三菱製薬株式会社医薬組成物
CA2696113A1 (en)2007-08-102009-04-02Burnham Institute For Medical ResearchTissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
CN106279283A (zh)2007-08-132017-01-04症变治疗公司新颖的葡糖激酶活化剂
WO2009029617A1 (en)2007-08-272009-03-05Kalypsys, Inc.Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
JP5227965B2 (ja)2007-10-032013-07-03独立行政法人理化学研究所ニトロトリアゾール誘導体、およびそれを用いる化合物の製造方法
KR20100089082A (ko)2007-10-152010-08-11아스트라제네카 아베조합 059
NZ585460A (en)2007-11-132013-02-22Icos CorpInhibitors of human phosphatidyl-inositol 3-kinase delta
CA2708391A1 (en)2007-12-132009-06-25Sri InternationalPpar-delta ligands and methods of their use
BRPI0820856A2 (pt)2007-12-132019-05-14Siena Bhiotech.S.P.A.anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos
US8399483B2 (en)2007-12-212013-03-19Ucb Pharma S.A.Quinoxaline and quinoline derivatives as kinase inhibitors
US7960397B2 (en)2007-12-282011-06-14Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
KR101660050B1 (ko)2008-01-042016-09-26인텔리카인, 엘엘씨특정 화학 물질, 조성물 및 방법
US8193182B2 (en)2008-01-042012-06-05Intellikine, Inc.Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BRPI0907248A2 (pt)2008-01-092019-02-26Pgxhealth, Llctratamento intratecal de dor neuropática com agonistas a2ar
WO2009100326A1 (en)2008-02-072009-08-13Cv Therapeutics, Inc.Abca-1 elevating compounds and the use thereof
WO2009100406A2 (en)2008-02-072009-08-13Synta Pharmaceuticals Corp.Topical formulations for the treatment of psoriasis
WO2009103022A1 (en)2008-02-132009-08-20Itherx Pharmaceuticals, Inc.Derivatives of substituted fused ring cycloindoles and methods of their use
TWI444384B (zh)2008-02-202014-07-11Gilead Sciences Inc核苷酸類似物及其在治療惡性腫瘤上的用途
EP2285216A4 (en)2008-02-212012-09-19Sequoia Pharmaceuticals Inc HIV PROTEASE INHIBITOR AND COMBINED CYTOCHROME P450 INHIBITOR
JP5547099B2 (ja)2008-03-142014-07-09インテリカイン, エルエルシーキナーゼ阻害剤および使用方法
US8993580B2 (en)2008-03-142015-03-31Intellikine LlcBenzothiazole kinase inhibitors and methods of use
WO2009117157A1 (en)2008-03-202009-09-24Amgen Inc.Aurora kinase modulators and method of use
WO2009118765A2 (en)2008-03-282009-10-01Panacea Biotec LimitedNovel monoamine re-uptake inhibitor
MX2010012583A (es)2008-05-302011-02-24Genentech IncCompuestos inhibidores de purina pi3k y métodos de uso.
US20090312406A1 (en)2008-06-122009-12-17Hsing-Pang HsiehCoumarin compounds and their use for treating viral infection
EA018028B1 (ru)2008-06-202013-04-30Амген Инк.Способ получения замещенных 2-аминотиазолонов
NZ590258A (en)2008-07-082013-10-25Intellikine LlcKinase inhibitors and methods of use
US20110224223A1 (en)2008-07-082011-09-15The Regents Of The University Of California, A California CorporationMTOR Modulators and Uses Thereof
CA2730610A1 (en)2008-07-162010-01-21Schering CorporationBicyclic heterocycle derivatives and their use as gpcr modulators
US8450344B2 (en)2008-07-252013-05-28Aerie Pharmaceuticals, Inc.Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
JP2011530596A (ja)2008-08-112011-12-22プレジデント アンド フェロウズ オブ ハーバード カレッジtRNA合成酵素の阻害のためのハロフジノン類似体およびそれらの使用
WO2010019921A2 (en)2008-08-152010-02-18The Regents Of The University Of CaliforniaBiomarkers for diagnosis and treatment of chronic lymphocytic leukemia
CN102186479A (zh)2008-09-102011-09-14凯利普西斯公司用于治疗疾病的组胺受体的氨基嘧啶抑制剂
CA2738313A1 (en)2008-09-232010-04-08Georgetown UniversityViral and fungal inhibitors
CA2738429C (en)2008-09-262016-10-25Intellikine, Inc.Heterocyclic kinase inhibitors
EP2177510A1 (en)2008-10-172010-04-21Universität des SaarlandesAllosteric protein kinase modulators
US8476431B2 (en)2008-11-032013-07-02Itellikine LLCBenzoxazole kinase inhibitors and methods of use
WO2010053998A1 (en)2008-11-052010-05-14Xenon Pharmaceuticals, Inc.Spiro-condensed indole derivatives as sodium channel inhibitors
EP3427739A1 (en)2008-11-132019-01-16Gilead Calistoga LLCTherapies for hematologic malignancies
US20110269779A1 (en)2008-11-182011-11-03Intellikine, Inc.Methods and compositions for treatment of ophthalmic conditions
AU2009322187B2 (en)2008-12-042015-02-19The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesPhosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of CNS disorders
SG172289A1 (en)2008-12-192011-07-28Boehringer Ingelheim IntCyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
EP2376079B1 (en)2009-01-132016-08-10Van Andel Research InstituteMethods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
US20110135655A1 (en)2009-01-132011-06-09PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine;Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
ES2598358T3 (es)2009-02-132017-01-27Ucb Pharma, S.A.Derivados de quinolina como inhibidores de PI3K quinasa
TW201038569A (en)2009-02-162010-11-01Abbott Gmbh & Co KgHeterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US20100280067A1 (en)2009-04-302010-11-04Pakala Kumara Savithru SarmaInhibitors of acetyl-coa carboxylase
CA2760791C (en)2009-05-072017-06-20Intellikine, Inc.Heterocyclic compounds and uses thereof
GB0908957D0 (en)2009-05-222009-07-01Ucb Pharma SaTherapeutic agents
JP2012527474A (ja)2009-05-222012-11-08エクセリクシス, インク.増殖性疾患に対するベンゾキサゼピンベースのpi3k/mt0r阻害剤
JP2012528165A (ja)2009-05-262012-11-12エクセリクシス, インク.PI3K/mTORの阻害剤としてのベンゾキサゼピンならびにそれらの使用および製造方法
SG182247A1 (en)2009-05-272012-08-30Hoffmann La RocheBicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US8173650B2 (en)2009-05-272012-05-08Genentech, Inc.Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
CN101602768B (zh)2009-07-172012-05-30河南省农科院农副产品加工研究所一种芝麻素和芝麻林素的提纯方法
US20120209047A1 (en)2009-07-292012-08-16Wright Michael EHomogeneous metallocene ziegler-natta catalysts for the oligomerization of olefins in aliphatic-hydrocarbon solvents
US9212177B2 (en)2009-08-052015-12-15Versitech LimitedAntiviral compounds and methods of making and using thereof
CA2775942A1 (en)2009-09-292011-04-07Xcovery Holding Company LlcPi3k (delta) selective inhibitors
US8106146B2 (en)2009-10-062012-01-31Medtronic, Inc.Therapeutic polymers and methods of generation
ES2520345T3 (es)2009-11-122014-11-11Ucb Pharma, S.A.Derivados de quinolina y quinoxalina en calidad de inhibidores de quinasa
EP2499144B1 (en)2009-11-122013-10-23UCB Pharma, S.A.Quinoline and quinoxaline derivatives as kinase inhibitors
WO2011058109A1 (en)2009-11-122011-05-19Ucb Pharma S.A.Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
EP2499195B1 (en)2009-11-132020-12-09Plastipak Packaging, Inc.Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
JP2013512878A (ja)2009-12-032013-04-18グラクソ グループ リミテッド新規化合物
WO2011072275A2 (en)2009-12-112011-06-16Nono, Inc.Agents and methods for treating ischemic and other diseases
AU2010330875B2 (en)2009-12-182013-08-01Amgen Inc.Heterocyclic compounds and their uses
AU2010341573B2 (en)2009-12-222016-10-13Vertex Pharmaceuticals IncorporatedIsoindolinone inhibitors of phosphatidylinositol 3-kinase
WO2011094890A1 (en)2010-02-022011-08-11Argusina Inc.Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
EP2536275A1 (en)2010-02-162012-12-26UWM Research Foundation, Inc.Methods of reducing virulence in bacteria
WO2011111880A1 (ko)2010-03-082011-09-15주식회사 메디젠텍세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
CN102206172B (zh)2010-03-302015-02-25中国医学科学院医药生物技术研究所一组取代双芳基化合物及其制备方法和抗病毒应用
EP2560636A4 (en)2010-04-232013-11-27Kineta Inc ANTIVIRAL CONNECTIONS
EP2560656A4 (en)2010-04-232013-11-27Kineta Inc ANTIVIRAL CONNECTIONS
EP2566329B1 (en)2010-05-042020-09-09Alkermes Pharma Ireland LimitedProcess for synthesizing oxidized lactam compounds
ES2593256T3 (es)2010-05-212016-12-07Infinity Pharmaceuticals, Inc.Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CN103038229B (zh)2010-05-262016-05-11桑诺维恩药品公司杂芳基化合物及其使用方法
US20120142701A1 (en)2010-05-282012-06-07The University Of Hong KongCompounds and methods for the treatment of proliferative diseases
EP2575818A4 (en)2010-06-032013-11-06Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK)
JP2013528228A (ja)2010-06-112013-07-08ギリアード カリストガ エルエルシーキナゾリノン化合物による選択した患者における血液系障害を処置する方法
WO2011163610A2 (en)2010-06-252011-12-29Rutgers, The State University Of New JerseyAntimicrobial agents
US8846931B2 (en)2010-07-052014-09-30Merck Patent GmbhBipyridyl derivatives
US8906943B2 (en)2010-08-052014-12-09John R. CashmanSynthetic compounds and methods to decrease nicotine self-administration
AR082799A1 (es)2010-09-082013-01-09Ucb Pharma SaDerivados de quinolina y quinoxalina como inhibidores de quinasa
WO2012037204A1 (en)2010-09-142012-03-22Exelixis, Inc.Inhibitors of pi3k-delta and methods of their use and manufacture
US8765773B2 (en)2010-10-182014-07-01Millennium Pharmaceuticals, Inc.Substituted hydroxamic acids and uses thereof
WO2012052540A1 (en)2010-10-212012-04-26Universitaet Des SaarlandesSelective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
AU2011323243A1 (en)2010-11-042013-05-23Amgen Inc.Heterocyclic compounds and their uses
AU2011326427B2 (en)2010-11-102016-01-07Infinity Pharmaceuticals Inc.Heterocyclic compounds and uses thereof
EP2640367A2 (en)2010-11-152013-09-25Exelixis, Inc.Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068096A2 (en)2010-11-152012-05-24Exelixis, Inc.Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EA201390766A1 (ru)2010-11-242013-11-29Экселиксис, Инк.БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
US20140378436A9 (en)2010-11-242014-12-25Exelixis, Inc.Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture
WO2012080727A2 (en)2010-12-142012-06-21Electrophoretics LimitedCasein kinase 1delta (ck1delta) inhibitors
US8765978B2 (en)2010-12-162014-07-01Transitions Optical, Inc.Method of making indeno-fused naphthol materials
US8987271B2 (en)2010-12-222015-03-24Eutropics Pharmaceuticals, Inc.2,2′-biphenazine compounds and methods useful for treating disease
NZ612909A (en)2011-01-102015-09-25Infinity Pharmaceuticals IncProcesses for preparing isoquinolinones and solid forms of isoquinolinones
EP2678342B1 (en)2011-02-252015-01-07Takeda Pharmaceutical Company LimitedN-substituted oxazinopteridines and oxazinopteridinones
US20140213630A1 (en)2011-03-082014-07-31Thomas DiacovoMethods and pharmaceutical compositions for treating lymphoid malignancy
BR112013022801A2 (pt)2011-03-112019-09-24Gilead Calistoga Llccombinações de terapia para malignidades hematológicas
AU2012229952A1 (en)2011-03-152013-04-18Abbvie Inc.Nuclear hormone receptor modulators
WO2012129562A2 (en)2011-03-242012-09-27The Scripps Research InstituteCompounds and methods for inducing chondrogenesis
CN102731492B (zh)2011-03-302016-06-29江苏恒瑞医药股份有限公司环己烷类衍生物、其制备方法及其在医药上的应用
MY179607A (en)2011-04-012020-11-11Genentech IncCombinations of akt inhibitor compounds and abiraterone, and methods of use
JO3733B1 (ar)2011-04-052021-01-31Bayer Ip Gmbhاستخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
KR101644051B1 (ko)2011-05-202016-08-01삼성전자 주식회사광전자 소자 및 적층 구조
UA114178C2 (uk)2011-07-012017-05-10Новартіс АгКомбінація, що включає інгібітор cdk4/6 і інгібітор pi3k, для лікування раку
CA2842190A1 (en)2011-07-192013-01-24Infinity Pharmaceuticals Inc.Heterocyclic compounds and uses thereof
EP2734520B1 (en)2011-07-192016-09-14Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
CN103635456B (zh)2011-07-262016-03-09山东亨利医药科技有限责任公司替加环素衍生物
CN103717571B8 (zh)2011-07-262017-05-17山东亨利医药科技有限责任公司9‑氨基甲基取代的四环素类化合物
CA2844670A1 (en)2011-08-122013-02-21Salk Institute For Biological StudiesNeuroprotective polyphenol analogs
MX2014002542A (es)2011-08-292014-07-09Infinity Pharmaceuticals IncCompuestos heterociclicos y usos de los mismos.
KR20140072028A (ko)2011-08-312014-06-12노파르티스 아게Pi3k- 및 mek-억제제의 상승작용적 조합물
WO2013044169A1 (en)2011-09-212013-03-28Nestec S.A.Methods for determining combination therapy with il-2 for the treatment of cancer
SG11201401625TA (en)2011-10-192014-05-29Pharmacyclics IncUse of inhibitors of bruton's tyrosine kinase (btk)
WO2013074583A1 (en)2011-11-142013-05-23The Broad Institute, Inc.Treatment and prognosis of lymphangioleiomyomatosis
WO2013086131A1 (en)2011-12-062013-06-13The Trustees Of The University Of PennsylvaniaInhibitors targeting drug-resistant influenza a
US8772541B2 (en)2011-12-152014-07-08University of Pittsburgh—of the Commonwealth System of Higher EducationCannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
WO2013090725A1 (en)2011-12-152013-06-20Philadelphia Health & Education CorporationNOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF
AR092790A1 (es)2012-02-012015-05-06Euro Celtique SaDerivados bencimidazolicos del acido hidroxamico
US8940742B2 (en)2012-04-102015-01-27Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
EP2861256B1 (en)2012-06-152019-10-23The Brigham and Women's Hospital, Inc.Compositions for treating cancer and methods for making the same
US8828998B2 (en)2012-06-252014-09-09Infinity Pharmaceuticals, Inc.Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP3550031A1 (en)2012-07-242019-10-09Pharmacyclics, LLCMutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
WO2014022830A2 (en)2012-08-032014-02-06Foundation Medicine, Inc.Human papilloma virus as predictor of cancer prognosis
WO2014046617A1 (en)2012-09-192014-03-27Agency For Science, Technology And ResearchCompositions and methods for treating cancer
US20140120060A1 (en)2012-11-012014-05-01Infinity Pharmaceuticals, Inc.Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
PL2914296T5 (pl)2012-11-012022-01-17Infinity Pharmaceuticals, Inc.Leczenie nowotworu z zastosowaniem modulatorów izoform kinazy PI3
US20140120083A1 (en)2012-11-012014-05-01Infinity Pharmaceuticals, Inc.Treatment of cancers using pi3 kinase isoform modulators
US20150283142A1 (en)2013-03-152015-10-08Infinity Pharmaceuticals, Inc.Treatment of cancers using pi3 kinase isoform modulators
JP6437441B2 (ja)2012-11-022018-12-12ティージー セラピューティクス インコーポレイテッド抗cd20抗体およびpi3キナーゼ選択的阻害剤の組み合わせ
EP2916868B1 (en)2012-11-082022-05-11Rhizen Pharmaceuticals S.A.Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
BR112015011147A8 (pt)2012-11-162019-10-01Merck Sharp & Dohmecomposto, composição farmacêutica, e, uso do referido composto
EP2953950B1 (en)2013-02-112021-01-13The Regents of The University of CaliforniaCompositions and methods for treating neurodegenerative diseases
US9481667B2 (en)2013-03-152016-11-01Infinity Pharmaceuticals, Inc.Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014151386A1 (en)2013-03-152014-09-25Infinity Pharmaceuticals, Inc.Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA2904198A1 (en)2013-03-152014-09-18Universite De GeneveUse of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
MX369503B (es)2013-04-082019-11-11Pharmacyclics LlcCombinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
JP6227889B2 (ja)2013-04-232017-11-08関東化學株式会社新規な有機金属錯体およびアミン化合物の製造方法
US20140377258A1 (en)2013-05-302014-12-25Infinity Pharmaceuticals, Inc.Treatment Of Cancers Using PI3 Kinase Isoform Modulators
CA2915250A1 (en)2013-06-132015-01-08Biomatrica, Inc.Cell stabilization
EA028319B1 (ru)2013-06-142017-11-30Джилид Калистога ЛлсИнгибиторы фосфатидилинозитол-3-киназы
ES2844200T3 (es)2013-06-202021-07-21Taiho Pharmaceutical Co LtdMétodo para predecir la eficacia terapéutica del inhibidor de PI3K/AKT/mTOR basándose en la expresión de PHLDA1 o PIK3C2B
UY35675A (es)2013-07-242015-02-27Novartis AgDerivados sustituidos de quinazolin-4-ona
US20150065431A1 (en)2013-08-272015-03-05Northwestern UniversityReducing cutaneous scar formation and treating skin conditions
CA2922805A1 (en)2013-09-112015-03-19Compugen Ltd.Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
US10111897B2 (en)2013-10-032018-10-30Duke UniversityCompositions and methods for treating cancer with JAK2 activity
PH12016500582B1 (en)2013-10-042023-06-30Infinity Pharmaceuticals IncHeterocyclic compounds and uses thereof
WO2015051241A1 (en)2013-10-042015-04-09Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
WO2015054099A1 (en)2013-10-082015-04-16Acetylon Pharmaceuticals, Inc.Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
WO2015054355A1 (en)2013-10-102015-04-16Acetylon Pharmaceuticals, Inc.Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
US20160244452A1 (en)2013-10-212016-08-25Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
CA2931615A1 (en)2013-11-262015-06-04Gilead Sciences, Inc.Therapies for treating myeloproliferative disorders
BR112016012794A2 (pt)2013-12-052017-08-08Acerta Pharma BvCombinação terapêutica de um inibidor de pi3k e um inibidor de btk
JP2017502016A (ja)2013-12-202017-01-19バイオメッド バレー ディスカバリーズ,インコーポレイティド1型mek阻害剤およびerk阻害剤の組み合わせを使用するがんの処置
WO2015095834A2 (en)2013-12-202015-06-25Biomed Valley Discoveries, Inc.Cancer treatments using erk1/2 and bcl-2 family inhibitors
EP4512480A3 (en)2013-12-202025-05-07Biomed Valley Discoveries, Inc.Cancer treatments using combinations of cdk and erk inhibitors
WO2015095831A1 (en)2013-12-202015-06-25Biomed Valley Discoveries, Inc.Cancer treatments using combinations of mtor and erk inhibitors
WO2015095842A2 (en)2013-12-202015-06-25Biomed Valley Discoveries, Inc.Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
JP6727127B2 (ja)2013-12-202020-07-29バイオメッド バレー ディスカバリーズ,インコーポレイティドPi3k/aktシグナル経路阻害剤およびerk阻害剤の組み合わせを使用するがん処置
WO2015095807A1 (en)2013-12-202015-06-25Biomed Valley Discoveries, Inc.Cancer treatments using combinations of egfr and erk inhibitors
US11007184B2 (en)2013-12-202021-05-18Biomed Valley Discoveries, Inc.Cancer treatments using combinations of type 2 MEK and ERK inhibitors
BR112016014481B1 (pt)2013-12-202022-11-08Biomed Valley Discoveries, IncUso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
AU2015206194A1 (en)2014-01-202016-07-28Gilead Sciences, Inc.Therapies for treating cancers
CN113616656B (zh)2014-03-192023-02-17无限药品股份有限公司用于治疗PI3K-γ介导的障碍的杂环化合物
SG11201607746QA (en)2014-03-212016-10-28Abbvie IncAnti-egfr antibodies and antibody drug conjugates
WO2015160975A2 (en)2014-04-162015-10-22Infinity Pharmaceuticals, Inc.Combination therapies
WO2015160986A2 (en)2014-04-162015-10-22Infinity Pharmaceuticals, Inc.Combination therapies
WO2015175966A1 (en)2014-05-162015-11-19Memorial Sloan Kettering Cancer CenterPlatelet-derived growth factor receptor mutations and compositions and methods relating thereto
WO2015179772A1 (en)2014-05-232015-11-26Concert Pharmaceuticals, Inc.Deuterated phenylquinazolinone and phenylisoquinolinone compounds
MX2016014864A (es)2014-05-272017-04-06Almirall SaCombinacion.
RS61406B1 (sr)2014-06-062021-03-31Bluebird Bio IncPoboljšane kompozicije t ćelija
JP2017535528A (ja)2014-10-032017-11-30ノバルティス アーゲー組み合わせ治療
WO2016054491A1 (en)2014-10-032016-04-07Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereof
JP6980649B2 (ja)2015-09-142021-12-15インフィニティー ファーマシューティカルズ, インコーポレイテッドイソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
WO2017161116A1 (en)2016-03-172017-09-21Infinity Pharmaceuticals, Inc.Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors

Also Published As

Publication numberPublication date
SG10201503886WA (en)2015-06-29
US20130345216A1 (en)2013-12-26
MX351028B (es)2017-09-28
EP3441392A1 (en)2019-02-13
US20190290636A1 (en)2019-09-26
JP2016210781A (ja)2016-12-15
US20160158239A1 (en)2016-06-09
IL243932A (en)2016-11-30
BR112012000968A8 (pt)2017-12-26
US20120149701A1 (en)2012-06-14
US11433065B2 (en)2022-09-06
KR101680406B1 (ko)2016-11-29
RU2746319C2 (ru)2021-04-12
MY175979A (en)2020-07-19
HUS2100048I1 (hu)2021-12-28
ES2538853T3 (es)2015-06-24
IL217181A (en)2016-02-29
EP2918589A1 (en)2015-09-16
DK2456444T3 (en)2015-05-11
ZA201200254B (en)2013-03-27
SG177641A1 (en)2012-02-28
CN106188059A (zh)2016-12-07
RU2016110024A3 (lt)2019-09-10
LTPA2021526I1 (lt)2021-12-10
NZ597595A (en)2014-08-29
MX2012000626A (es)2012-03-26
BR112012000968A2 (pt)2017-12-05
EP3150609A1 (en)2017-04-05
NZ706506A (en)2016-11-25
CN109912599B (zh)2021-11-02
CY2021034I1 (el)2022-03-24
CY2021034I2 (el)2022-03-24
CY1116424T1 (el)2017-02-08
HRP20150586T1 (hr)2015-07-03
RU2016110024A (ru)2018-11-23
US20180098983A1 (en)2018-04-12
AU2010274075A1 (en)2012-02-09
JP5944313B2 (ja)2016-07-05
RU2012105071A (ru)2013-08-20
US8193182B2 (en)2012-06-05
CA2768307C (en)2018-02-13
IL243932A0 (en)2016-04-21
US9206182B2 (en)2015-12-08
US20120245169A1 (en)2012-09-27
UA109878C2 (uk)2015-10-26
US8569323B2 (en)2013-10-29
EP2456444B1 (en)2015-03-18
AU2010274075B2 (en)2015-01-22
US20170281614A1 (en)2017-10-05
NZ619727A (en)2015-05-29
JP6158395B2 (ja)2017-07-05
SI2456444T1 (sl)2015-07-31
US20140341894A1 (en)2014-11-20
PH12020550450A1 (en)2021-06-07
EP3441392B1 (en)2021-12-15
US20160031886A1 (en)2016-02-04
UA121192C2 (uk)2020-04-27
RU2582676C2 (ru)2016-04-27
MX379814B (es)2025-03-11
NL301140I1 (lt)2021-11-03
HK1170491A1 (en)2013-03-01
US8785456B2 (en)2014-07-22
CA2768307A1 (en)2011-01-20
MY168762A (en)2018-12-04
US20090312319A1 (en)2009-12-17
US9522146B2 (en)2016-12-20
IN2012DN00943A (lt)2015-04-10
US20250170122A1 (en)2025-05-29
NO2021047I1 (no)2021-11-10
US20220265637A1 (en)2022-08-25
CN109912599A (zh)2019-06-21
CN102711767A (zh)2012-10-03
FIC20210039I1 (fi)2021-11-03
EP3150609B1 (en)2018-09-12
CN102711767B (zh)2016-08-03
US9216982B2 (en)2015-12-22
PT2456444E (pt)2015-06-09
NL301140I2 (nl)2021-11-15
PH12015502432A1 (en)2017-01-16
WO2011008302A1 (en)2011-01-20
LUC00237I2 (lt)2025-02-03
RU2582676C3 (ru)2022-01-17
BR112012000968B8 (pt)2021-05-25
EP2918589B1 (en)2016-11-02
BR112012000968B1 (pt)2021-05-04
PL2456444T3 (pl)2015-08-31
IL217181A0 (en)2012-02-29
JP2012533541A (ja)2012-12-27
US20200222384A1 (en)2020-07-16
EP2456444A4 (en)2012-12-05
HK1213257A1 (en)2016-06-30
SMT201500141B (it)2015-09-07
US9655892B2 (en)2017-05-23
EP2456444A1 (en)2012-05-30
KR20120097479A (ko)2012-09-04
CN106188059B (zh)2019-02-01

Similar Documents

PublicationPublication DateTitle
LTPA2021526I1 (lt)
BE2015C040I2 (lt)
BR112012008195A2 (lt)
BRPI0924307A2 (lt)
BRPI1006562A2 (lt)
BR112012008267A2 (lt)
BRPI1006661A2 (lt)
BR112012000607A2 (lt)
BR122021004633A2 (lt)
BR112012012487A2 (lt)
BR112012003080A2 (lt)
BR112012000665A2 (lt)
BR122017024704A2 (lt)
BR112012003853A2 (lt)
BR112012012080A2 (lt)
BR112012009797A2 (lt)
BR112012009446A2 (lt)
BR112012009703A2 (lt)
BRPI0924534A2 (lt)
BRPI1005795A2 (lt)
BR112012010357A2 (lt)
BR112012001263A2 (lt)
BR112012007656A2 (lt)
BR112012000159A2 (lt)
BR112012002627A2 (lt)

[8]ページ先頭

©2009-2025 Movatter.jp